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The intestinal microbiota plays critical roles in human physiology and diseases. While 
recent research has revealed many mechanisms by which gut microbiota influences host 
immunity to defend against invading pathogens, how microbiota directly antagonizes 
pathogen virulence is less studied. In particular, gut microbiota produces large amounts 
and varieties of small molecules that may impact both host immunity and pathogen 
virulence. In this thesis, I describe how fatty acids, derived from both gut microbiota and 
diet, contribute to attenuation of virulence of enteric pathogen Salmonella. 
In Chapter 1, I review how dietary and microbiota metabolites affect different aspects of 
host-microbe interactions. These metabolites are categorized into microbial-associated 
molecular patterns and microbiota-derived secondary metabolites. Small molecules 
reviewed in this chapter not only enhances host innate and adaptive immunity, but also 
directly inhibit virulence of invading pathogens, providing colonization resistance to the 
host. In some cases, pathogens could exploit these metabolites as environmental signals 
to enhance its survival and expansion. These findings highlight the importance of 
understanding the intricate interactions between host and microbiota, and should provide 
insights in developing microbiota-targeting therapeutics for host physiology, immunity, and 
pathogen resistance.  
In Chapter 2, I describe a mechanism by which microbiota-derived short-chain fatty acids 
inhibit virulence of Salmonella Typhimurium. Short-chain fatty acids can inhibit Salmonella 
virulence, but the molecular mechanism(s) remain poorly characterized. We use a 
chemical reporter strategy to identify molecular targets of short-chain fatty acids in 
Salmonella. I demonstrate that alkynyl-functionalized short-chain fatty acids can be 
metabolized and covalently attached to proteins in Salmonella. Proteomic analysis reveal 
that HilA, a key virulence transcription regulator, is short-chain fatty acylated. I employ 
Amber Suppression Technology and CRISPR-Cas9 genome editing to faithfully mimic 
butyrylation on endogenous HilA. Biochemical and functional characterization show that 
acylation of HilA has site-specific effect, and K90 butyrylation affect HilA DNA-binding 
activity and Salmonella invasion in mice. Overall, our results discover a mechanism by 
which gut microbiota provides resistance against Salmonella through short-chain fatty 
acids.  
In Chapter 3, I describe long-chain fatty acylation of HilA and biochemical characterization 
of HilA. I find that dietary long-chain fatty acids potently inhibit Salmonella virulence. 
Chemical proteomics with alkynyl-functionalized long-chain fatty acids reveal proteins that 
are long-chain fatty acylated in Salmonella, including HilA. Modification by long-chain fatty 
acids on HilA is post-translationally N-linked. Moreover, with photo-crosslinking unnatural 
amino acid, we discover that HilA forms homo-oligomers in Salmonella. Our data suggest 
that dietary long-chain fatty acids may interfere pathogenesis of Salmonella through post-
translational modification, and further structural characterization of HilA may reveal novel 
target for treatment of Salmonella infection.  
The projects described in this thesis underscore the important roles microbiota and dietary 
metabolites have played in host immunity and enteric pathogen restriction.  
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Chapter 1 
Mechanisms of dietary and microbiota metabolites 





Recent advances on microbiota profiling and mechanisms have revealed its critical roles in human 
health and disease. More than 90% of human microbiota resides in the gastrointestinal tract, 
making the intestinal microbiota the major target of microbiome research.  Intestinal microbiome 
as a whole broadly affects host physiology and responses to intestinal and systemic diseases. 
The composition of the intestinal microbiota is dynamic and is influenced by environmental factors 
including host diet, exposure to drugs, infection as well as genetic factors.  
The intestine, placed in the latter part of the digestive tract, is a melting pot of complex 
constituents. Food in the intestine has to be broken down into smaller pieces, in terms of both 
physical form and chemical composition. Smaller dietary molecules, derived from plants and 
animals, could be absorbed by the intestine, or be converted by intestinal microbiota into 
secondary metabolites. Moreover, indigestible macromolecules could also be utilized by intestinal 
microflora and be fermented into smaller and accessible nutrients. In fact, intestinal microbiota 
produces significant amounts of metabolites that can function as signaling molecules to modulate 
host physiology and disease (Fig. 1.1).  
 
This chapter summarizes recent studies of specific metabolites derived from both diet and 
microbiota, and their potential biochemical effects on both host and microbes. While biopolymers 
common in all kingdoms of life, including double-stranded DNA and RNA, lipopolysaccharide 
(LPS), and lipopeptides, are long recognized as ligands for pattern recognition receptors (PRRs), 
especially Toll-like receptors (TLRs) on host cells, this chapter will focus on small, soluble 
metabolites specifically from microbiota and diet. Some of these metabolites have been recently 
reviewed (1, 2), and this chapter aims to expand the scope and include recent advances. A 
molecular understanding of intestinal microbiota–host interactions is pivotal to medicine and 
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human health. Insight into the function of dietary and microbiota metabolites could help design 
targeted therapeutics against a variety of diseases and advance personalized medicine. 
 
Figure 1.1. Dietary and microbiota-derived metabolites modulate host physiology and 
immunity and pathogen virulence. 
 
 
Microbe-Associated Molecular Patterns 
 
Microbe-associated molecular patterns (MAMPs) are molecules derived from microbiota that are 
specifically recognized by PRRs of the host and could trigger downstream signaling events, 
leading to host resistance or tolerance towards microbes. While these molecules were first 
characterized through studies on host-pathogen interactions and initially termed “pathogen-
associated molecular patterns (PAMPs)”, they are now accepted as critical molecules from 
commensal microbes as well. Depending on the context, these molecules could stimulate either 
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pro- or anti-inflammatory responses. Being the first family of innate PRRs identified, Toll-like 
receptors (TLRs) and their cognate ligands have been described in detail elsewhere (3), so this 
chapter will focus on other more recently identified MAMPs as well as their receptors in the host. 
 
 
Figure 1.2. Microbe-associated molecular pattern metabolites. Their corresponding host 
receptors are listed after the colon. (A) MDP : NOD2. (B) iE-DAP : NOD1. (C) HBP : TIFA. (D) α-
galactosylceramide : CD1d ;  sphingosine-1-phosphate : S1PR4. (E) c-di-AMP, c-di-GMP: STING, 
ERAdP.  
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Muramyl dipeptide (MDP) and γ-D-glutamyl-meso-DAP (iE-DAP) 
Peptidoglycan (PG) is one of the most abundant macromolecules in a bacterial cell, typically 
forming a mesh-like structure that encloses the cytoplasmic membrane (4–6). PG is structurally 
distinct from cell wall components in archaea and single-celled eukaryotes, making it ideal as a 
PAMP for mammalian cells. Peptidoglycan is composed of polysaccharide chains with alternating 
ß-1,4-linked N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc) residues, which 
are crosslinked via short peptides (4, 5). These peptides contain D-amino acids such as D-alanine 
or D-glutamate, as well as unusual non-proteinogenic amino acids, such as meso-diaminopimelic 
acid (meso-DAP). The amino acid sequence of the peptides and the structure of crosslinks are 
variable between bacterial species (7–9). Although PG is hidden from the innate immune system 
in Gram-negative bacteria by an outer membrane, soluble PG turnover products and its 
biosynthesis intermediates could be released from both intact and lysed cells into the surrounding 
milieu. Mammalian cells utilize multiple PG recognition receptors to detect these MAMPs and 
initiate an inflammatory response.  
Nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) are cytosolic proteins 
that play a pivotal role in the regulation of the host innate immune system (10). They act as 
scaffolding proteins that assemble signaling complexes that trigger NF-κB and MAPK signaling 
pathways. In particular, NOD1 and NOD2 sense PG fragments from bacteria. NOD1 senses 
peptide fragments of PG, with dipeptide γ-D-glutamyl-meso-DAP (iE-DAP) (Fig. 1.2B) as the 
minimal unit (11, 12), which is conserved among most Gram-negative bacteria and some Gram-
positive bacteria (13). NOD2 senses muramyl dipeptide (MDP) (Fig. 1.2A) (14), which is found in 
nearly all Gram-positive and Gram-negative bacteria. Following sensing these microbial PG 
fragments, NOD1 and NOD2 directly recruit receptor-interacting protein 2 (RIP2) through caspase 
recruiting domain (CARD)-CARD interactions (15, 16). This leads to activation of IKK complex 
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and phosphorylation as well as degradation of inhibitor IκB, and further causes NF-κB to 
translocate to the nucleus and activate the innate immune response (17). NOD1 and NOD2 
directly senses invading bacterial pathogens in vitro and in vivo, such as Gram-negative Shigella 
flexneri (18), Salmonella Typhimurium (19), Gram-positive Mycobacterium tuberculosis (20), and 
Listeria monocytogenes (21). Interestly, our laboratory recently showed that a secreted peptidase 
SagA from Enterococcus faecium could protect both worms and mice from Salmonella 
Typhimurium infection, and the protection is mediated through PG fragments generated by SagA 
enzymatic activity (22, 23). Further experiments showed that SagA generates GlcNAc-(1–4)-
MurNAc dipeptide (GlcNAc-MDP), which could stimulate NOD2 signaling in mammalian cells (Kim 
B et al., unpublished). Indeed, the protective effect by SagA and SagA-expressing bacteria 
depends on the expression of NOD2 in vivo (23). These results suggest that commensal bacteria 
in the gut could harness stimulatory effects of PG fragments to prime the host innate immune 
system against enteric pathogens. 
Heptose-1,7-bisphosphate (HBP) 
Lipopolysaccharide (LPS) is a vital cell membrane component in Gram-negative bacteria (24). 
LPS has been well characterized as a ligand for TLR4 and stimulate MyD88-dependent TRIF-
dependent innate immune response (3). LPS are large molecules consisting of lipid A as the 
membrane anchor, and a polysaccharide part composed of O-antigen (or O polysaccharide) and 
core oligosaccharide (25). The core oligosaccharide directly attaches to lipid A, and commonly 
contains sugars such as heptose. Recently, Gaudet et al. reported that heptose-1,7-bisphosphate 
(HBP) (Fig. 1.2C), a key biosynthesis intermediate of LPS, could trigger inflammatory response 
in the mammalian host (26). They further identified TRAF-interacting protein with forkhead-
associated domain (TIFA) as the critical mediator of signaling axis, although direct sensor of HBP 
in host cells remains unknown. HBP induces TIFA phosphorylation and oligomerization at 
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lysosomal compartments, which would then trigger oligomerization of ubiquitinylated TRAF6, and 
ultimately NF-B activation pathway as well as innate immune gene expression. Interestingly, 
while HBP could be released from lysed Gram-negative bacteria, intact Neisseria species actively 
excrete HBP into its surrounding environment. Neisseria gonnorrhoeae may use HBP as a 
stimulator of NF-B pathway, which could drive HIV gene expression as well as viral shedding 
and transmission in Neisseria and HIV coinfection setting (27, 28). Elucidation of the full signaling 
pathway of HBP will not only provide essential insights for controlling infection but will also serve 




Sphingolipids are a class of lipids characterized by a long-chain amino alcohol sphingoid 
backbone with an amide-bound fatty acyl chain. While sphingolipid production is ubiquitous in 
eukaryotes, only a small subset of bacteria could produce sphingolipids. To date, known 
sphingolipid-producing bacteria include the majority of the Bacteroidetes phylum together with a 
few members of the Chlorobi phylum (29), as well as a subset of Alphaproteobacteria and 
Deltaproteobacteria (30, 31). The initial step of sphingolipid synthesis involves the condensation 
of an amino acid and a fatty acid via the serine palmitoyltransferase (SPT) enzyme, which is highly 
conserved in both eukaryotes and bacteria (32). Within the human gut, members of the 
Bacteroidetes are known to produce sphigophospholipids that resemble sphingomyelin, an 
abundant sphingolipid in mammalian membranes (33, 34). This raises the question of whether 
bacteria in the gut has evolved to exploit sphingolipid signaling pathways in their hosts.  
In fact, Bacteroides fragilis, a common gut commensal, synthesizes α-galactosylceramide (α-
GalCerBf) (Fig. 1.2D), which is structurally similar to the synthetic potent CD1d activator KRN7000 
(34). However, the subtle structural difference renders α-GalCerBf as CD1d antagonist, which 
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leads to reduced colonic invariant natural killer T (iNKT) cells and protection against induced 
colitis (35).  
Certain sphingolipids from gut microbiota that resembles sphingosine-1-phosphate (S1P) (Fig. 
1.2D) may also signal through S1P receptor S1PR4, a GPCR that specifically expressed in 
lymphoid tissue (36). S1PR4 signaling induces the chemotaxis of natural killer cells and dendritic 
cells, as well as modulates Th2 immune responses (37). The recent discovery of N-acyl amides 
produced by gut microbiota could also act as specific ligands for S1PR4 (38), which suggests that 
gut microbiota may have a variety of molecules that could modulate host immunity through 




Besides bacterial cell wall components that are essential for bacterial survival, bacteria as a 
community also use a variety of signaling molecules to communicate with each other for collective 
behavior. One particular class of signaling molecules are cyclic nucleotides that include cyclic 
adenosine 3',5'-monophosphate (cGMP), cyclic guanosine 3',5'-monophosphate (cAMP), 3',3'-
cyclic dimeric GMP (c-di-GMP) (Fig. 1.2E), 3',3'-cyclic GMP-AMP (3',3'-cGAMP), and 3',3'-cyclic 
dimeric AMP (c-di-AMP) (Fig. 1.2E). They mediate numerous critical pathways in the bacterial 
community, such as biofilm formation, chemotaxis, motility, and virulence (39, 40).  
 
Mammalian hosts have also evolved specific sensors for cyclic nucleotides as means of immune 
recognition. Indeed, c-di-GMP could be specifically sensed by STING (stimulator of IFN genes; 
also known as MITA, ERIS, MPYS, and TMEM173), an ER-localized transmembrane protein (41, 
42). Its C-terminal cytosolic domain (CTD) could bind to c-di-GMP (43), and the binding event 
triggers recruitment and activation of IRF3. After a series of phosphorylation events mediated by 
TBK1, IRF3 would dimerize and enter cell nucleus to activate transcription of relevant genes, 
9 
 
resulting in type I interferon production. Interestingly, mammalian cells also sense non-
physiological double-stranded DNA (dsDNA) through STING (44). The cyclic GMP-AMP synthase 
(cGAS) in the cytosol could bind to tiny amounts of dsDNA and adopt a conformational change, 
which in turn catalyze cytosolic GTP and ATP to synthesize 2',3'-cyclic GMP-AMP (2',3'-cGAMP) 
(45), which is structurally similar to c-di-GMP. The endogenous 2',3'-cGAMP could bind even 
more potently to STING and activate type I interferon response. These findings suggest mammals 
have used STING as a sensor for bacteria and dsDNA virus infection, all mediated through cyclic 
dinucleotides.  
 
Since c-di-AMP is also very similar to c-di-GMP and 2',3'-cGAMP, it is thought to bind to STING 
and trigger innate immune response as well. However, STING affinities towards c-di-AMP and c-
di-GMP (Kd = 1 to 5 uM) are much weaker than that towards 2',3'-cGAMP (Kd = 51 nM), making 
its identity as a bona fide physiological sensor of c-di-AMP in question (46). Recently, Xia et al. 
showed that ERAdP, an ER adaptor protein, directly senses c-di-AMP (46). C-di-AMP binds to 
the CTD of ERAdP at high affinity (Kd = 76 nM), which leads to recruitment of TAK1. This would 
initiate activation of transcription factor NF-B and induce production of pro-inflammatory 
cytokines in immune cells. This ERAdP-TAK1 signaling axis is required for the eradication of 
Listeria monocytogenes infection. 
 
Microbiota-derived secondary metabolites 
 
Gut microbiota metabolizes nutrients from host diet, uses them for energy source as well as 
bacterial cell building blocks. At the same time, microbes also generates a broad range of 
secondary metabolites. Some may be regarded as side products of bacterial metabolism 
pathways, and some appear to have no apparent functions on bacterial community at first sight. 
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As shown in the following, many secondary metabolites may not directly impact microbiota itself, 
but play pivotal roles in regulating host immunity, and even directly antagonize invading 
pathogens, thus maintaining the homeostasis of microbiota as well as the host.  
 
Short-Chain Fatty Acids (SCFA) 
 
Undigested complex dietary fibers are abundant substrates for bacterial fermentation in the colon; 
therefore they are also termed microbiota-accessible carbohydrates (MACs) (47). Their main 
metabolic products are short-chain fatty acids (SCFAs), including acetic acid, propionic acid, and 
butyric acid (Fig. 1.3A). SCFA concentrations in the gut range from 5 mM to 140 mM (48), 
depending on the location of the intestine, microbiota composition, and the MAC content of the 
host diet. SCFAs are critical energy sources not only for the gut microbiota itself but also for 
intestinal epithelial cells (IECs), especially colonocytes. In addition to acting as local substrates 
for energy production, SCFAs have diverse regulatory functions on host physiology and immunity, 
which recent exciting discoveries continue to reveal.  
 
SCFAs are ligands for G protein-coupled receptors (GPCRs), and thereby act as signaling 
molecules that influence the expansion and function of many cell lineages. GPCRs responding to 
SCFAs include GPR43 (also known as FFAR2), GPR41 (also known as FFAR3) and GPR109A 
(also known as HCAR2), which are expressed by numerous cell types, including immune cells 
and IECs. GPR43 expression is necessary for SCFA-induced neutrophil chemotaxis (49) and the 
expansion and suppressive function of forkhead box P3 (FOXP3)+ regulatory T (Treg) cells (50–
52). SCFA-mediated activation of GPR109A, a receptor that responds to both niacin and butyric 
acid, prevented colitis and colon carcinogenesis through increased expression of anti-
inflammatory effector molecules by monocytes and induced differentiation of Treg cells (53). 
Binding of SCFAs to GPR43 and GPR109A on IECs also activated inflammasome assembly and 
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increased production of the downstream inflammatory cytokine IL-18 (54), which prevented a 
colitogenic phenotype, enhanced IEC integrity, and fortified IEC barrier function (55). Outside the 
gut, SCFA–GPR43 interactions decrease chemotaxis and inflammatory gene expression in 
neutrophils (56), and downregulates gout-associated inflammation by mediating inflammasome 
assembly and immune cell clearance of monosodium urate crystals (57). SCFAs blocked DC 
maturation through GPR41 signaling and ameliorated allergic airway inflammation (58).  
The GPR43-dependent effects of SCFAs on host physiology also extend to the central nervous 
system (CNS). The maturation and function of microglia, which are the resident macrophages of 
the CNS, were dependent on the gut microbiota, and the maintenance of microglia homeostasis 
required SCFAs and GPR43 (59). However, SCFAs can also exacerbate disease. In an α-
synuclein (αSyn)-dependent Parkinson's disease mice model, SCFAs from the gut accelerate 
αSyn aggregation and microglia activation in mice brain, thus exacerbate motor dysfunction (60). 
Therefore, the immunomodulatory effects of SCFAs depend on the context and cell type under 
investigation.  
 
SCFA are also inhibitors of histone deacetylases (HDACs). Several studies demonstrate that 
SCFA-induced HDAC inhibition downregulates of NF-κB activity and pro-inflammatory innate 
immune responses in neutrophils (49, 61), macrophages (62, 63) and dendritic cells (DCs) (58, 
64). Moreover, SCFAs also influence peripheral T cells, particularly regulatory T (Treg) cells, 
through HDAC inhibition (50–52). HDAC inhibition by SCFAs increased FOXP3 expression, 
leading to amplified Treg cell numbers, increased Treg cell frequency, and enhanced Treg cell 
suppressive function in vivo (65). Only high millimolar SCFA concentrations are sufficient to 
perturb HDAC function (66), and their effects may require specific transporters (64). SCFA-driven 
inhibition of HDACs tends to promote a tolerogenic, anti-inflammatory cell phenotype that is 
crucial for maintaining immune homeostasis, and this activity supports the concept that the 




SCFAs not only modulate host immunity, but also metabolism of host intestinal epithelial cells. 
Enterocytes use butyrate for -oxidation, which depletes oxygen diffused from blood vessel and 
lamina propria (67). Butyrate also signals through PPAR- to limit the availability of oxidative 
species in the gut lumen (68). This helps maintenance of anaerobic environment in the gut. 
Depletion of butyrate by antibiotics or gut inflammation switches metabolic program in enterocytes 
from -oxidation to glycolysis, leading to accumulation of lactate and oxygen in the gut lumen, 
both of which drives expansion of facultative anaerobes, including Salmonella (67).  
 
SCFAs also directly modulate virulence of various pathogens. In particular, SCFAs could 
differentially regulate expression of Salmonella virulence genes. While acetate enhances the 
virulence gene expression through BarA/SirA two-component system signaling in Salmonella 
(69), propionate and butyrate could downregulate the expression (69, 70). Specifically, propionate 
may post-translationally modify HilD, a key transcription regulator of Salmonella virulence, and 
affect its stability (71). Loss of butyrate utilization pathway in Salmonella attenuates Salmonella 
virulence (72), but the mechanism through which butyrate represses Salmonella virulence 
remains unknown. We are proposing that butyrate dampens Salmonella virulence through post-
translational modification on HilA, another key transcription regulator of Salmonella virulence 
(Chapter 2). More studies are needed to investigate the immunomodulatory functions and 






Vitamin A (VA) is a lipophilic micronutrient obtained by dietary ingestion of pro-vitamin A 
carotenoids (such as β-carotene) and retinyl esters (RE). Humans are not able to synthesize VA, 
thus depend on dietary supply for maintenance of multiple physiological processes throughout 
the human body (reviewed in (73)). After intake, carotenes are enzymatically converted in the 
intestine into retinol, which is transported from the gut lumen into the cell cytoplasm and is rapidly 
converted to RE or to retinoic acid (RA) (74), with all-trans-RA (atRA) (Fig. 1.3B) being the 
physiologically most abundant and well-studied. RA could be sensed by receptors that are broadly 
classified into two subgroups, retinoic acid receptor (RAR) and retinoid X receptor (RXR). In the 
absence of ligands, RAR/RXR heterodimers constitutively bind to retinoic acid response elements 
(RARE) and suppress the transcription of target genes (75). Both atRA and 9-cis-RA can bind to 
RAR/RXR, displacing the corepressors and activating target gene expression (76–78). Most of 
the RA immune-related functions signal through the RAR/RXR pathway, primarily driven by atRA 
acting through RARα (79). 
 
VA is crucial to the establishment of oral immunological tolerance against food antigens (80, 81), 
and its deficiency might contribute towards food allergies and inflammatory bowel diseases (IBD). 
Notably, atRA participates in multiples steps in the establishment of oral immunological tolerance 
(80). AtRA could dramatically expand pre-mucosal DCs (pre-µDCs) population that expresses 
α4β7, a gut homing receptor on lymphocytes (82). Furthermore, atRA in the lamina propria of 
intestine enhances differentiation of pre-µDCs into CD103+ DCs, a critical DC population for 
sensing antigens from the gut lumen (83). In combination with CD103+ DCs and TGF-β, atTA 
increases the generation of FOXP3+ Treg cells in mesenteric lymph nodes (MLNs) (84), 
restricting Th17 differentiation (85–87), as well as induces in T cells expression of α4β7 and 
CCR9, another gut homing receptor. Treg cells induced in this manner can produce anti-
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inflammatory IL-10 and migrate to the intestine to promote tolerance (88, 89). Innate lymphoid 
cells (ILCs) in the MLN could also be induced to express CCR9 and α4β7 by atRA, which leads 
to ILC migration to the intestine (90). The concentrations of atRA in the small intestine follows a 
proximal to distal (i.e., duodenum to colon) decreasing gradient (91, 92), which correlates with 
the differential distribution of different ILCs population along the gastrointestinal tract (93). 
Therefore, it may be reasonable to speculate that atRA might be involved in the regionalization of 




Gut lumen is filled with digested nutrients from the diet, including amino acids. In particular, 
aromatic amino acids (tryptophan, phenylalanine, tyrosine, histidine) could be metabolized by gut 
microbiota and converted into aromatic acids through a series of oxidative or reductive pathways. 
Of note, several of them, including indoleacetic acid, indolepropionic acid (IPA) (Fig. 1.3C), and 
indolelactic acid (ILA) (Fig. 1.3C), could be absorbed by the intestine and circulate in the mice 
serum (94). Aromatic acids are well-known agonists of aryl-hydrocarbon receptor (AhR), a ligand-
activated transcription factor involved in lymphoid system development (95, 96), immune 
response (97), and toxic response (98). Aromatic acids also activate pregnane X receptor (PXR), 
another crucial nuclear receptor involved in intestinal permeability and toxic response (99). 
Therefore, elevated aromatic acids level in systemic sites induced by microbiota have a potentially 
profound impact on host physiology.  
Indeed, Lactobacillus reuteri catabolizes L-tryptophan and produces ILA, which activates AhR in 
CD4+ T cells, allowing downregulation of the transcription factor ThPOK and differentiation into 
CD4+CD8αα+ double-positive intraepithelial T lymphocytes (DP IELs) (100). DP IELs have a 
regulatory function complementary to that of Tregs and promote tolerance to dietary antigens 
(101). Lactobacillus species also produce indole-3-aldehyde, another derivative of tryptophan, 
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which is also an AhR ligand and contributes to AhR-dependent IL-22 production. This leads to 
balanced mucosal response, provides colonization resistance to the fungus Candida albicans, 
and mucosal protection from inflammation (102). In another study, Wlodarska et al. found that 
several Peptostreptococcus species could produce indoleacrylic acid (IAA) (Fig. 1.3C), which 
promotes intestinal epithelial barrier function and mitigates inflammatory responses through AhR 
(103). On the other hand, Venkatesh et al. showed that IPA produced by Clostridium sporogenes 
could downregulate enterocyte TNF- while it promotes tight junction between IECs through 
activation of PXR in vivo, which also depend on TLR4 (104). Recently, Dodd et al. engineered C. 
sporogenes to make it defective in producing IPA, and comparing to mice colonized with wild-
type C. sporogenes, mice with C. sporogenes mutant have increased intestinal permeability and 
adaptive immune response to C. sporogenes (94). These exciting studies highlight how microbial-




Mucosal-associated invariant T (MAIT) cells are innate-like T cells that comprise up to 10% of the 
peripheral blood T-cell population of humans (105), and they are involved in microbial response  
(106, 107) as well as autoimmune diseases (108). MAIT cells can be activated by most bacteria 
and yeast through antigen presentation by MR1, an MHC-I like molecule (109, 110). However, 
the specific antigens presented by MR1 had been long elusive. During the structural determination 
of MR1, Kjer-Nielsen et al. found that MR1 could bind to 6-formyl pterin (6-FP), a 
photodegradation product of folic acid (111). Even though 6-FP could not activate MAIT cells, it 
provided the first hint on what ligands MR1 could potentially bind. Further functional assays 
revealed that several riboflavin (Vitamin B2) biosynthesis precursors, namely reduced 6-
hydroxymethyl-8-D-ribityllumazine (rRL-6-CH2OH) (Fig. 1.3D), 7-hydroxy-6-methyl-8-D-
ribityllumazine (RL-6-Me-7-OH) (Fig. 1.3D), and 6,7-dimethyl-8-D-ribityllumazine (RL-6,7-diMe) 
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(Fig. 1.3D), could activate MAIT cell TCR in an MR1-dependent manner (111). Interestingly, 
riboflavin itself could not activate MAIT cells, and microbes that do not have riboflavin biosynthesis 
pathway could not activate MAIT cells (111).  
In a follow-up study, Corbett et al. found that MAIT-cell activation requires microbial genes 
encoding enzymes that form 5-amino-6-D-ribitylaminouracil (5-A-RU), an early intermediate in 
bacterial riboflavin synthesis (112). Although 5-A-RU does not bind MR1 or activate MAIT cells 
directly, it does undergo non-enzymatic reactions with other small molecules from microbes, such 
as glyoxal and methylglyoxal. The resulting adducts, 5-(2-oxoethylideneamino)-6-D-
ribitylaminouracil (5-OE-RU) (Fig. 1.3D) and 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil 
(5-OP-RU) (Fig. 1.3D), even though unstable, could bind to MR1 as reversible covalent Schiff 
base complexes (112). Thus, MR1 can capture, stabilize and present chemically unstable 
pyrimidine intermediates as potent antigens to MAIT cells. Since riboflavin is synthesized by 
plants and most bacteria and yeasts but not by animal cells, while MAIT invariant TCR is 
evolutionarily conserved among mammals and other vertebrates (113), these two findings 
exemplify co-evolution of invariant TCRs, MHC-I like molecules, and their cognate microbial-
specific small molecule antigens. 
 
Secondary bile acids 
 
Bile acids are amphipathic molecules synthesized from cholesterol in the liver. They are 
physiological detergents that help secrete metabolites into the gastrointestinal tract. In the 
intestines, bile acids help intestinal absorption of dietary fats, fat-soluble vitamins, and other 
nutritions (114). Cholic acid (CA) and chenodeoxycholic acid (CDCA) are the dominant primary 
bile acids in humans. Of note, deoxycholic acid (DCA) (Fig. 1.3E) is a secondary bile acid formed 
by bacterial dehydroxylation of cholic acid; lithocholic acid (LCA) (Fig. 1.3E) is formed by the 
analogous dehydroxylation of chenodeoxycholic acid. DCA and LCA could be further conjugated 
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with taurine or glycine by gut microbiota, generating conjugated bile acids, including 
taurodeoxycholic acid (TDCA).  
In recent decades, bile acids are recognized not only as digestive surfactants, but also as 
important signaling molecules in a broad range of biological functions, including glucose and lipid 
metabolism, energy homeostasis, and the modulation of immune response (114–116). The 
regulatory functions of bile acids are mainly the result of activation of a nuclear receptor, the 
farnesoid X receptor (FXR, NR1H4) (117–119), and a cell surface GPCR, TGR5 (GPBAR-1) (120, 
121). FXR activation inhibits pro-inflammatory cytokine production in vivo, and limits bacterial 
overgrowth as well as intestinal permeability (122). TGR5 activation leads to inhibition of pro-
inflammatory NF-κB pathway (123, 124), as well as activation of endothelial iNOS and NO release 
(125, 126). Collectively, FXR and TGR5 signaling promotes intestinal barrier function and exerts 
immune modulation in the gut.  
Interestingly, while CDCA is the most potent ligand for FXR (127–129), LCA and taurine-
conjugated LCA are most potent endogenous ligands for TGR5 (130–132). This indicates that 
microbiota-dependent bile acid metabolism plays critical roles in regulating host signaling 
pathways and physiology outcomes. Indeed, abnormal bile acid metabolism has been associated 
with liver injury, metabolic disorders, cardiovascular diseases, as well as digestive system 
diseases, such as inflammatory bowel disease (IBD) and colorectal cancer (133–135).     
 
Secondary bile acids also direct influence virulence of enteric pathogens (136, 137). Bile acids 
could activate Type III Secretion System 2 (T3SS2) in Vibrio parahaemolyticus (138). Specifically, 
TDCA binds to VtrA/VtrC complex, activating VtrB and V. parahaemolyticus virulence (139). 
Besides, secondary bile acids inhibit spore germination, growth, and toxin production of 
Clostridium difficile (140). Clostridium scindens, a bile acid 7-dehydroxylating intestinal 
bacterium, enhances resistance to C. difficile infection in a secondary bile acid dependent manner 
(141). Moreover, bile acids repress invasion gene expression in Salmonella by post-translational 
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destabilization of HilD (142). These findings have implications for the rational design of 
microbiome-based diagnostics and therapeutics for individuals with enteric infections.  
 
Taurine, histamine, and spermine 
 
Besides acids, gut microbiota could also produce amines, including taurine, histamine, and 
spermine (Fig. 1.3F). Taurine is scavenged by gut microbes from taurine-conjugated bile acids 
produced by the host, while some bacteria could also perform taurine conjugation on bile acids. 
Histamine and spermine could be synthesized from histidine and ornithine. In inflammasome-
deficient mice model, Levy et al. discovered that compared to wild-type mice, Asc-/- 
inflammasome-defective mice have decreased the abundance of taurine and increased the 
abundance of histamine and spermine, which correlate with suppression of inflammasome activity 
(143). Colonic explants demonstrated that taurine activates, while histamine and spermine 
suppress NLRP6 inflammasome activity. NLRP6 inflammasome could induce intestinal IL-18 
production, which orchestrates colonic anti-microbial peptide (AMP) expression. The 
inflammasome-AMP axis, in turn, could regulate intestinal microbial composition, establishing a 
stable mutualism between host innate immune system and gut microbiota (143). 
 
Long-chain N-acyl amides 
 
The human microbiome is believed to encode functions that are important to human health; 
however, little is known about the specific effector molecules that commensals use to interact with 
the human host. Functional metagenomics provides a systematic way of surveying commensal 
DNA for genes that encode effector functions. Cohen et al. examined 3,000 Mb of metagenomics 
DNA cloned from fecal samples of three IBD patients and screened for effector gene clusters that 
activate NF-κB. One of the effector gene clusters come out of screening was recovered from all 
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three patient libraries, and it encodes for the production of N-acyl-3-hydroxypalmitoyl-glycine 
(commendamide), which resembles long-chain N-acyl amides that function as mammalian 
signaling molecules (144). They further showed that commendamide activates G2A/GPR132, a 
GPCR that is implicated in the modulation of immune cell function, autoimmunity, and 
atherosclerosis. In a follow-up study, Cohen et al. performed a bioinformatics analysis of human 
microbiome data to find bacterial enzymes that produce N-acyl amides. They identified 143 
unique N-acyl synthase genes, which are enriched in gastrointestinal bacteria (38). Exogenous 
expression of these genes in Escherichia coli indicated that they produce N-acyl amides of six 
major families that are structurally similar to human GPCR ligands, including N-acyl serinol (Fig. 
1.3G), which resembles the GPR119 ligand oleoylethanolamide. Profiling of some N-acyl amides 
against 240 human GPCRs revealed specific interactions, especially among receptors expressed 
in the gastrointestinal tract (38). Interestingly, mice colonized with bacteria expressing the 
synthase of N-acyl serinols showed reduced blood sugar levels in an oral glucose-tolerance test, 
consistent with the action on host GPR119 (38). These findings represent one of the first 
examples of microbe-derived small molecules affecting host physiology and highlight the use of 




Similar to the discovery of microbiota-produced long-chain N-acyl amides, Guo et al. have used 
metagenomic bioinformatics to find a new family of nonribosomal peptide synthetase (NRPS) 
gene clusters from human microbiome (145). By expressing some of the most prevalent NRPS 
gene clusters (>90% samples), they found new molecules were produced, belonging to a family 
of pyrazinones and dihydropyrazinones, some of which were found with similar approaches from 
Staphylococcus aureus (146). Even though pyrazinones have been implicated as inhibitors of 
host proteases, they have poor in vitro affinity and activity. The authors found that these 
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pyrazinones were initially liberated from NRPSs as dipeptide aldehydes (Fig. 1.3H), which would 
undergo spontaneous cyclization and oxidation in the presence of oxygen (145). Indeed, under 
physiological pH and anaerobic condition, dipeptide aldehydes were stable enough to remain in 
active form, being highly potent, cell-permeable protease inhibitors. N-octanoyl-Met-Phe-H, an N-
acylated dipeptide aldehyde that could not cyclize and be oxidized, is also a major product. 
Quantitative activity-based protein profiling (ABPP) showed that Phe-Phe-H, one dipeptide 
aldehyde representative, specifically inactivates cathepsin L, with minimal cross-reactivity to other 
cathepsins as well as other host proteins (145). These findings again demonstrate interesting 
interactions between host and microbiota and provide new lines of evidence on mutualism 






Figure 1.3. Microbiota-derived secondary metabolites. Their corresponding host receptors are 
listed after the colon. (A) Short-chain fatty acids : GPCRs, HDACs. (B) All-trans-retinoic acid : 
RAR, RXR. (C) Aromatic acids : PXR, AHR. (D) Riboflavin precursors : MR1. (E) Secondary bile 
acids : GPBAR1, NR1H4. (F) Taurine, histamine, and spermine: NLRP6.  (G) N-acyl serinol : 






All the examples discussed above highlight the intricate interactions between host and its resident 
gut microbiota, resonating with a comment made more than two millennia ago by Hippocrates, 
"all disease begins in the gut". Bacterial density reaches a staggering 1011 organisms per gram in 
the colon, making this bacterial community the principal source of microbial metabolites in the 
human body. O'Hara and Shanahan proposed in 2005 that the gut microbiota represents a 
‘microbial organ' (147), because it resides as a structural unit and produces metabolites at 
concentrations that promote health, analogous to an endocrine system. While the ‘microbial 
organ' concept is generally accepted (148), it is problematic to define what a ‘healthy microbial 
organ' should look like, because the comparison of the gut microbiota composition between 
different healthy individuals reveals minimal overlap on the species level (149). Recently, 
Byndloss and Baumler proposed that anaerobiosis is the hallmark of mammalian gut (150), 
thereby driving the composition of the microbial community towards a dominance of obligate 
anaerobes, which is critical for maintaining gut homeostasis (68). In contrast, dysbiosis, a state 
of microbial organ dysfunction, is characterized by failure to limit oxygen level in the gut and 
expansion of facultative anaerobes, including most enteric pathogens (150). This germ-organ 
theory instructs a shift from microbial community profiling towards understanding host-mediated 
control of microbial organ ecology. It calls for mechanistic follow-up studies aiming at 
understanding trophic networks, the influence of host physiology on the microbial ecosystem, and 
the role that microbiota-derived metabolites have in health and disease. This might be a move in 












Microbiota-derived short-chain fatty acids inhibit Salmonella virulence 






The intestinal microbiota is important for host metabolism as well as immune development and is 
associated with human diseases. While the gut microflora is known to protect the host from 
invading pathogens, the underlying mechanism(s) have been elusive. Of note, short-chain fatty 
acids (SCFA) produced by commensal bacteria have been shown to inhibit key bacterial virulence 
pathways, such as type III secretion system (T3SS) in Gram-negative enteric bacterial pathogens, 
but the molecular mechanism(s) are still under investigation. The major limitation in understanding 
the functions of SCFA has been identifying the direct biochemical targets of these microbial 
metabolites. We applied bio-orthogonal alkyne-fatty acid reporters to directly identify the 
biochemical targets of SCFA in Salmonella Typhimurium, a Gram-negative enteric pathogen 
responsible gastroenteritis in humans. With in-gel fluorescence profiling, click chemistry-mediated 
enrichment and mass spectrometry-based proteomics, I found that exogenous short-chain fatty 
acids can inhibit T3SS of Salmonella and covalently modify key virulence transcriptional regulator 
HilA. The modification was not susceptible to enzymatic acylation or deacylation mediated by Pat 
and CobB. Via amber suppression technology and CRISPR-Cas9 genome editing technique, bio-
orthogonal stable lysine acylation mimic was incorporated site-specifically to endogenously 
expressed HilA in Salmonella, and it revealed that fatty-acylation on K90, K324, and K456 of HilA 
impaired its function to activate virulence gene expression, and decreased corresponding 
Salmonella mutants’ infectivity to HeLa cells. In particular, I showed that fatty-acylation on K90 of 
HilA impaired its DNA-binding activity, decreasing Salmonella invasion in mice. These studies are 
crucial for elucidating fundamental mechanisms of microbiota-mediated resistance on bacterial 







The intestinal microbiota of mammals is composed of 1013-1014 cells, which outnumbers total cell 
numbers in the host (151). It consists of about 1000 different bacterial species that regulate host 
metabolism (152), resistance to gut pathogens (153), as well as immune system development 
and homeostasis (154). Dysregulation of the microbiota is associated with a variety of host 
immune disorders, including inflammatory bowel disease (IBD) (155), allergy (156), and diabetes 
(157). Fecal transplant from healthy donors to patients has achieved satisfactory results in treating 
recurrent C. difficile infection and other intestinal diseases (158). The mechanisms by which 
commensal bacteria modulate host immune system and protect against enteric pathogens have 
been difficult to elucidate due to the complex interactions between the host and its microbiota and 
enteric pathogens. 
 
S. enterica is a Gram-negative intracellular pathogen that causes gastroenteritis and typhoid fever 
worldwide (159). Once ingested, Salmonella traverses the gut to the small intestine, where a set 
of virulence genes are activated to promote gut inflammation as well as invasion of the intestinal 
epithelia, allowing Salmonella to replicate and disseminate throughout the host (160). Systemic 
infection associated with typhoid fever is mediated by two Salmonella pathogenicity islands (SPI) 
that encode Type 3 Secretion Systems (T3SS) for bacterial invasion, dissemination, and 
replication inside host cells (159, 160). Specifically, SPI-1 is important for Salmonella invasion, 
while SPI-2 is crucial for Salmonella replication in host cells (161). Genetic and biochemical 
studies have demonstrated that T3SS form multi-protein complexes to inject a variety of bacterial 
protein effectors into host cells for Salmonella pathogenesis (159, 160). These Salmonella 
virulence programs are regulated by a variety of environmental factors, including the host 




Of note, short-chain fatty acids (SCFA) produced by commensal bacteria, including propionate 
and butyrate, have been shown to inhibit T3SS in Salmonella enterica serovar Typhimurium (Stm) 
(69–71). SCFA have been implicated in inhibiting Salmonella virulence through transcriptional (69) 
and post-translational regulation (71), but the molecular mechanism(s) are not well studied. 
Understanding the effects of short-chain fatty acids on Stm will help elucidate the interactions 
between host, commensal bacteria, and enteric pathogen, and guide new treatment and 
prevention to enteric bacterial pathogens. 
 
Over the last decade, bio-orthogonal chemistry has emerged as a powerful tool to rapidly 
investigate biological activities with minimal perturbation to the biological system. Copper-
catalyzed azide–alkyne cycloaddition (CuAAC), or more commonly “click chemistry”, is the most 
widely used bio-orthogonal reaction, in which Cu(I) cation catalyzes cycloaddition between azide 
and alkyne, forming stable covalent bonds between two molecules attached with azido or alkynyl 
group. We have developed bio-orthogonal acylation reporters over the past few years that have 
enabled rapid and robust detection of fatty-acylation of proteins in both bacteria and mammalian 
cells. LCFA reporters have been applied to detect reversible S-palmitoylation in mammalian cells 
(163) and to detect lipoproteins in bacteria (164). SCFA reporters are applied to probe acetylation 
in mammalian cells (165). Compared to traditional fatty-acylation detection methods, these fatty-
acylation reporters facilitate rapid detection compared to radioactive isotope fatty acids labeling, 
which may take up to weeks for detection, and robust reproducibility as compared to detection by 
fatty-acylation-specific antibodies. In this work, I set out to apply SCFA chemical reporter to study 
how SCFA inhibit the virulence of Stm, specifically the post-translational modification (PTM) of 
virulence-related factors, and directly address the functional consequence of short-chain fatty-




During the last 15 years, Amber Suppression Technology has been developed to enable 
incorporation of Unnatural Amino Acids (UAA) site-specifically in proteins of interest in vivo. It 
harnesses an orthogonal pair of tRNAPyl and aminoacyl-tRNA synthetase derived from 
Methanosarcina species, which can recognize unnatural amino acid (UAA) and incorporate it onto 
protein-encoding mRNA bearing an amber codon (TAG), a stop codon if naturally read by the 
translation system. In vitro directed evolution has created a variety of synthetase mutants that can 
incorporate a broad range of functionalized UAAs. Amber Suppression Technology, coupled with 
CRISPR-Cas9 genome editing technique, allows us to install functional and stable lysine-
acylation mimic site-specifically in endogenously expressed HilA in Stm. 
 
Genetic tools in Salmonella have been developed over the years and greatly facilitate the genetic 
research in Salmonella. In particular, genome editing techniques based on Lambda Red 
Recombination System (166) have been widely used for genetic knock-out and knock-in in 
Salmonella (167). Nevertheless, these editing approaches rely on insertion of an antibiotic 
resistance cassette in the genome for positive selection. Even if the cassette can be eliminated 
with FLP recombinase, it inevitably leaves a “scar” sequence on the genome, potentially causing 
unintended side effects on the cell (166). Recently, CRISPR-Cas9 genome editing technique has 
been widely adopted in scientific community for precise and scarless genome editing in various 
organisms, from bacteria (168) to mammals (169–171). Previously it was reported that CRISPR-
Cas9 genome editing system could be applied in Escherichia coli with high editing efficiency (168). 
Cas9 protein and guide-RNA (sgRNA) were introduced to E. coli in two separate plasmids, pCas9 
and pCRISPR, along with transformation of editing template and expression of Lambda Red 
recombinase. Given the similarity between E. coli and Stm, we tried to use the same protocol in 




In this chapter, I demonstrate that HilA, a key virulence regulator of SPI-1 T3SS in Stm, is short-
chain fatty-acylated at five lysine residues in vivo. I showed that Lysine Butyrylation Mimic (KBM) 
UAA is a faithful and stable mimic of lysine butyrylation, and incorporating KBM at different sites 
of HilA results in varied functional consequence. In particular, I provided evidence that HilA K90 
acylation affects its DNA-binding ability, decreases SPI-1 gene expression, and impairs 






Short-chain fatty acids inhibit Salmonella virulence 
 
In mammalian gut, concentrations of SCFA varies, of which median is about 10 mM. I observed 
that butyrate (Fig. 2.1A), a major SCFA present in the gut, did not inhibit Stm growth in vitro at 
concentration of 10 mM (Fig. 2.1B). However, 10 mM butyrate decreased Stm invasion ability to 
HeLa cells (Fig. 2.1C), and inhibited expression level of Stm SPI-1 effector genes such as sipA, 
as shown by quantitative reverse–transcription PCR (qRT-PCR) (Fig. 2.1D). This suggest that 
butyrate inhibits Stm virulence through antagonizing transcription and expression of Stm SPI-1 
effector proteins. SCFA are metabolized in Stm and may result in the production of a panel of 
highly reactive acyl intermediates, including acyl-CoA and acyl-phosphate (172), which may lead 
to an extensive increase of post-translational modifications on a variety of proteins, leading to 
altered regulatory functions (173) and enzymatic activities (174). Therefore, we hypothesized that 
SCFA may inhibit Stm virulence through acylation of key virulence regulators, which might affect 






Figure 2.1. Short-chain fatty acids inhibit Salmonella virulence. (A) Structure of butyrate and Alk-3. (B) 
Growth curve of Stm 14028 WT in SPI-1 inducing LB in the presence of 10 mM C-4, 10 mM mM Alk-3, or 
same volume of water. (C) Gentamicin protection assay of Stm incubated with or without 10 mM Alk-3 
infecting HeLa cells at MOI=10. (D) Expression of SPI-1 gene sipA was measured by qRT-PCR from Stm 
with or without 10 mM alk-3 incubation. 
 
Proteomic analysis of acylated proteins in Salmonella 
 
To identify acylated proteins in Salmonella, I employed SCFA chemical reporter alk-3 (pentynoate) 
(Fig. 2.1A). Alk-3 behaved similarly to its natural counterpart butyrate, as it retained the ability to 
inhibit Stm invasion to HeLa cells (Fig. 2.1C) and inhibited expression level of sipA (Fig. 2.1D) at 
10 mM, but did not inhibit Stm growth (Fig. 2.1B). This suggests it may have similar mode of 
action as butyrate to inhibit Stm virulence. To visualize acylated proteins with alk-3, I incubated 
Stm culture with 10 mM alk-3, and harvested total cell lysates for CuAAC reaction with azide-
functionalized Rhodamine (az-Rho, Fig. 2.2A). SDS-PAGE followed by in-gel fluorescence 
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scanning demonstrated that alk-3 metabolically labeled a diverse repertoire of proteins in Stm 
(Fig. 2.2C). To identify these acylated proteins, I performed Label-Free Quantitative (LFQ) 
Proteomics analysis on Stm proteome with or without alk-3 labeling. Stm cell lysates were reacted 
with an azido-biotin affinity tag (az-biotin, Fig. 2.2B). Alk-3 labeled proteins were enriched by 
streptavidin beads, and digested by Trypsin/LysC mix on-bead. Digested peptides were 
processed and identified by Liquid Chromatography–tandem Mass Spectrometry (LC-MS/MS). 
The resulting spectrum were searched with MaxQuant (176) and quantified with Perseus (177). I 
identified ‘hits’ as proteins enriched for more than 2-fold in alk-3 samples and P-value less than 
0.05. With this approach, I selectively identified 56 proteins labeled by alk-3 compared to control 
samples (Fig. 2.2D, Appendix 2.1). Of these proteins, 34 of the hits (61%) were categorized as 
metabolism-related proteins. However, only 6 proteins in these hits (11%) were directly related to 
Stm virulence. Notably, HilA, a master transcriptional activator of Stm SPI-1 virulence (178, 179), 
was one of the most prominent hits in the data set. 
 
HilA is acylated in Salmonella 
 
HilA is a master transcription regulator of SPI-1, belonging to OmpR/PhoB family of regulatory 
proteins. HilA activates the inv/spa and prg operons, encoding components of the T3SS 
apparatus (180, 181), and the sic/sip operon, encoding a chaperone and secreted proteins (182). 
HilA is essential for Salmonella virulence, as hilA gene deletion in Salmonella abolishes its 
secretion of SPI-1 effectors (183) (Fig. 2.3A) and its infectivity to cells (184) (Fig. 2.3B). HilA 
protein is predicted by NCBI Conserved Domains Search to contain an N-terminus DNA-binding 
domain (DBD) and a Tetratricopeptide Repeat (TPR) domain near its C-terminus, but no atomic 
structure of HilA is available to date (Fig. 2.3C). It is reported that HilA is acetylated at 5 different 
lysine residues (185), namely K90, K231, K324, K456, and K533. Robetta Full-chain Protein 
Structure Prediction Server (186) predicted that all of these 5 lysine residues located at the 
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surface of the protein, suggesting that they may be accessible for acylation (Fig. 2.3D). Moreover, 
K57 was predicted to be critical for protein-DNA interaction between HilA and its DNA partner. 
Therefore, I used HilA K57 mutant as a loss-of-function control. I also chose K527 as a neutral 
control, as it was not implicated to have any functional role. 
 
 
Figure 2.2. Proteomic analysis of acylated proteins in Salmonella. (A) Molecular structure of azido-
Rhodamine (az-Rho). (B) Molecular structure of azido-PEG3-biotin (az-biotin). (C) Salmonella cell lysates 
were reacted with az-Rho by CuACC, and proteins were separated by SDS-PAGE for visualization by 
fluorescence gel scanning (top). Coomassie blue staining demonstrates comparable loading (bottom). (D) 
Salmonella cell lysates were reacted with az-biotin by CuAAC for the enrichment of alk-3–labeled proteins 
with streptavidin beads and identification by mass spectrometry. LFQ proteomic analysis Identified proteins 
that were enriched by alk-3 (top right corner), which were colored according to their annotated biological 






Figure 2.3.  HilA is essential for Salmonella virulence. (A) Secretion assay of Stm WT, Stm hilA, and 
Stm hilA overexpressing HilA-HA-His. The secreted SPI-1 effector proteins were precipitated from 
supernatant with trichloroacetic acid and run on SDS-PAGE, followed by Coomassie Blue staining. (B) 
Gentamicin protection assay of Stm, Stm hilA, and Stm HilA-HA infecting HeLa cells at MOI=10. (C) 
Predicted domains of HilA and lysine residues that are reported to be acetylated (orange), as well as K57 
and K527 chosen to serve as controls (navy). DBD, DNA-binding domain. TPR, tetratricopeptide repeat 
domain. (D) Predicted structure of HilA by Robetta Full-chain Protein Structure Prediction Server. DBD is 





To study HilA in more detail, I subcloned HilA into pBAD plasmid and appended HA tag and His6 
tag to the C-terminus of HilA. HilA-HA-His6 was well expressed upon arabinose induction in Stm, 
and it functionally rescued secretion deficiency in Stm hilA mutant (Fig. 2.3A). To confirm that 
HilA was indeed acylated, Stm overexpressing HilA-HA-His6 was grown in medium with alk-3, 
and CuAAC in-gel fluorescence scanning of cell lysates demonstrated that HilA was labeled by 
alk-3 (Fig. 2.4A). Moreover, I purified HilA-HA-His6 protein from Stm incubated with either 
propionate or butyrate, and enriched acylated fraction with anti-propionyllysine or anti-
butyryllysine antibody. LC-MS/MS analysis of digested peptides from these fractions identified 5 
lysine residues out of 34 in HilA were acetylated, propionylated, or butyrylated (Fig. 2.4B, 2.4C, 
Appendix 2.2), consistent with previous report (185). Modification occupancies were estimated 
based on area of modified and unmodified peptides in LC-MS/MS (Fig. 2.4B). K324 and K456 
unmodified peptides, when fully digested, are too short to be detected, therefore the modification 
occupancy were not determined.  
 
Acylation is a dynamic process, which may involve both acyltransferases and deacylases ‘writing’ 
and ‘erasing’ acylation on proteins. To investigate whether acylation on HilA is regulated by 
acyltransferase and deacylase in Salmonella, HilA-HA-His6 was co-expressed with Gcn5-like 
Protein Acyltransferase (Pat), or the only known protein deacylase in Salmonella, CobB. CuAAC 
in-gel fluorescence scanning showed that while CobB could decrease alk-3 labeling level on 
Salmonella proteome (Fig. 2.4D), alk-3 labeling level on HilA was not affected by either Pat or 





Figure 2.4. HilA is acylated in Salmonella. (A) Stm overexpressing HilA-HA-His were incubated with 
water or 10 mM Alk-3 before CuAAC with az-Rho, SDS-PAGE in-gel fluorescence scanning (top), and 
immunoblotting (bottom). (B) Table of lysine residues (column) and short-chain acylation types (row) 
identified by LC-MS/MS (tick), and their estimated modification occupancy in parentheses. ND, not 
determined. (C) MS/MS spectrum of HilA K90 butyrylated peptide and K324 propionylated peptide as 
representative MS/MS spectrums of acylated HilA peptide. (D)(E) Salmonella overexpressing HilA-HA-His, 
as well as Pat-Flag or CobB-Flag, were incubated with or without alk-3 during overexpression. Total cell 
lysates (D) and anti-HA immunoprecipitated samples (E) were analyzed with SDS-PAGE in-gel 





Installing stable acylation mimic on HilA in Salmonella 
 
Next I set out to pinpoint the effects of lysine fatty-acylation on the function of HilA. Conventional 
approaches include mutating lysine residues to glutamines as mimicry to lysine acylation. 
However, glutamine bears a polar terminal acylamine and is relatively small, which is significantly 
different from the relatively nonpolar internal secondary amide and bulky steric hindrance in N-
acyllysine. To achieve better mimicry of lysine acylation on HilA protein, we decided to apply 
amber suppression technology to site-specifically engineer HilA. 
 
First I tested incorporation of a panel of acyllysines, namely acetyllysine (AcK), propionyllysine 
(PrK), and butyryllysine (BuK) (Fig. 2.5A), which have been reported to be incorporated into 
proteins in bacteria (187, 188). I found that in Salmonella, AcK and PrK were not detected to be 
incorporated at K90 in HilA (Fig. 2.5B). BuK was poorly incorporated, and could be barely 
detected by anti-HA and pan anti-BuK immunoblotting (Fig. 2.5B). I also raised a custom site-
specific polyclonal antibody against HilA butyrylated K90 (anti-HilAK90Bu), and HilA-K90BuK was 
poorly detected as well (Fig. 2.5B). 
 
To incorporate an unnatural amino acid that can be efficiently incorporated into proteins in 
Salmonella, and faithfully mimics lysine acylation at the same time, we decided to use a lysine 
analog UAA, Lysine Butyrylation Mimic (KBM, Nε-pent-4-ynyloxy-carbonyl-L-Lysine) (Fig. 2.5A) 
(189). It bears carbamate at -N and an alkynyl group at the terminus. This unique structure 
serves as lysine acylation mimic at -N on lysine residues, and protects itself from being 
deacylated by endogenous deacylases, while at the same time enables robust detection via 
CuAAC. I demonstrated that KBM could be readily incorporated via Methanosarcina barkeri 
pyrrolysine-tRNA synthetase ASF mutant and tRNACUA, and into over-expressed HilA at K90 at 
similar levels compared to wild type, which could be detected by immunoblotting (Fig. 2.5B) and 
37 
 
in-gel fluorescence scanning (Fig. 2.5C). Importantly, HilAK90KBM protein could be 
immunoblotted by both pan anti-BuK antibody and anti-HilAK90Bu antibody (Fig. 2.5B), but not 




Figure 2.5. Installing Stable acylation mimic on HilA in Salmonella. (A) Molecular structure of 
acetyllysine (AcK), propionyllysine (PrK), butyryllysine (BuK), and lysine butyrylation mimic (KBM). (B) (C) 
Salmonella with HilA-HA-His or HilAK90tag-HA-His construct, as well as PylRS-WT or –ASF mutant 
plasmid, were incubated with or without AcK, PrK, BuK, or KBM during overexpression. Total cell lysates 
(B) were analyzed with SDS-PAGE in-gel fluorescence scanning (top), Coomassie Blue staining (middle), 
and anti-HA immunoblotting (bottom). Anti-HA immunoprecipitated samples (C) were immunoblotted for 
HA, AcK, PrK, BuK, or HilAK90Bu. 
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Optimizing CRISPR-Cas9 Genome Editing in Salmonella 
To assay effects of acylation on HilA in a more physiologically relevant setting, we sought to 
incorporate KBM into endogenously expressed HilA protein. Therefore, we would need site-
specific amber codon mutations in the hilA gene in Salmonella genome, with no additional 
mutations to complicate the phenotype outcome. We decided to use CRISPR-Cas9 genome 
editing in Salmonella, a technique that could generate scarless and precise mutations in genome. 
I tried to directly employ CRISPR-Cas9 genome editing protocol in E. coli (168) to Stm. Briefly, 
sgRNA sequence is subcloned into pCRISPR, and Stm expressing Lambda Red Recombination 
System (pKD46 plasmid) is transformed with pCas9, pCRISPR-sgRNA, and a double-stranded 
DNA (dsDNA) editing template. Bacteria is selected on agar plates for colonies containing both 
pCas9 and pCRISPR-sgRNA. However, I found that this protocol resulted in very high false-
positive rate and editing efficiency was extremely low, with estimation that less than 5% of 
colonies on the plate were successfully edited. 
To optimize the CRISPR-Cas9 genome editing system in Stm, we first deleted a guide RNA 
sequence with unknown function in pCas9 to minimize off-target effect of Cas9. This new plasmid, 
pWJ297, contains coding sequence of Streptococcus pyogenes Cas9 (SpCas9), 
Chloramphenicol resistance gene, and direct repeats flanking two BsaI restriction sites for 
subcloning of sgRNA sequence. SpCas9 requires Protospacer Adjacent Motif (PAM), namely 
NGG nucleotide sequence (or CCN on complementary strand), to correctly pair sgRNA in the 
genome and create dsDNA break (190). Ideally, sequence to be modified should be within 10 
base-pairs of PAM for sufficient discrimination between non-perfect-match (i.e. edited) and 
perfect-match (i.e. unedited) sequences by Cas9 (168). However, this was not feasible in many 
cases, especially when targeted sequence was in an AT-rich region. To increase editing efficiency 
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in these circumstances, I introduced synonymous co-mutation of nearest PAM together with 
targeted sequence, and used sgRNA specific for that PAM to guide Cas9 (Fig. 2.6A). As an 
example, I set out to mutate K90 in HilA, and synonymous PAM co-mutation strategy increased 
editing efficiency from 0/11 to 1/15 (Fig. 2.6B). 
After screening the colonies that were selected for pWJ297 and pCRISPR, I found that most of 
them were false-positive, suggesting that CRISPR-Cas9 system did not impose selection 
pressure high enough against unedited clones. Interestingly, many of these false-positive colonies 
could not grow when purified on a new agar plate selecting for pWJ297 and pCRISPR. I surmised 
that Stm has an intrinsic suppressive mechanism to inactivate exogenous CRISPR-Cas9 system, 
and this inactivation could be abrogated when Stm is in rapid growth state. Therefore, I collected 
all colonies from the plate of first-round selection, suspended them in liquid medium LB with 
corresponding antibiotics, and grew them to early stationary phase. The resulting culture was 
plated again on selection agar plate. This liquid selection protocol further increased frequency of 
successfully edited clones (Fig. 2.6C). 
After successful genome editing, pWJ297 and pCRISPR need to be cured to eliminate any 
unnecessary complications. While pWJ297 could be efficiently cured by one round of purification 
on plain agar plate, pCRISPR was very resistant to curing, taking up to one month of serial 
purification, which is presumably due to its small size and high copy number. To facilitate the 
entire editing process, I incorporated sgRNA sequence directly at pWJ297 BsaI cloning site, 
sparing the usage of pCRISPR. The editing efficiency of pWJ297-sgRNA is similar to pWJ297 + 
pCRISPR combination (data not shown), while the former was cured in about 1 day. This 




Figure 2.6. Optimizing CRISPR-Cas9 Genome Editing in Salmonella with co-mutation and liquid 
selection. (A) Scheme of synonymous co-mutation of nearest PAM. In addition to K90A (AAA to GCA) 
mutation, c243g synonymous mutation eliminates PAM sequence in blue. (B) PCR screening of Stm 
genome editing of hilAK90A with (right) or without (left) PAM co-mutation. Absence of PCR amplification 
band indicates successful editing. (C) PCR screening of Stm genome editing of hilAK456tag before (left) or 
after (right) additional liquid selection step. Absence of PCR amplification band indicates successful editing. 
 
The Lambda Red Recombination system encodes three proteins: Exo, Gam, and Beta. Exo and 
Gam, required for dsDNA recombination, are not required for single-stranded DNA (ssDNA) 
reombination, in which case only Beta is required (191). SsDNA recombination efficiency is much 
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higher than dsDNA in E. coli because ssDNA has higher transformation efficiency (191). 
Therefore, I decided to use ssDNA template when editing small pieces of genome, for example, 
site-specific mutation of single codons on endogenous genes. CRISPR-Cas9 genome editing with 
ssDNA provided higher editing efficiency compared to that with long dsDNA template that has the 
same mutation site (Fig. 2.7A). I observed no significant difference of editing efficiency among 
ssDNA templates that matches either the same strand or the complementary strand of sgRNA, 
nor between templates matching either the leading or the lagging strand of genome (Fig. 2.7B). 
To confirm that CRISPR-Cas9 genome editing in Salmonella did not introduce additional off-target 
mutations, I performed Next-Generation whole-genome sequencing on Stm 14028S WT, Stm 
14028S HilA-HA, and Stm 14028S HilAK90tag-HA strains (Table 2.1). Compared to WT, HilA-
HA and HilAK90tag-HA did not contain additional mutations other than intended insertion and 
substitution that could seemingly have functional impact. Therefore, CRISPR-Cas9 genome 
editing was specific in introducing intended mutations in Salmonella.  
To summarize, I have optimized CRISPR-Cas9 genome editing protocol to facilitate the editing 
process in Salmonella (Fig. 2.7C). The entire procedure takes 3–4 days for completion, 



















Figure 2.7. Optimizing CRISPR-Cas9 Genome Editing in Salmonella. (A) PCR screening of Stm 
genome editing of hilAK456Q with dsDNA (left) or ssDNA (right) as editing template. Absence of PCR 
amplification band indicates successful editing. (B) PCR screening of Stm genome editing of hilAK456A 
(top), K527tag (middle), or K533tag (bottom) with sense or anti-sense ssDNA as editing template. Absence 
of PCR amplification band indicates successful editing. Editing success rates as well as targeting strands 
of gRNA are listed on the right. (C) Scheme of optimized CRISPR-Cas9 genome editing in Salmonella. 
Salmonella is first transformed with pKD46, then is transformed with pWJ297-spacer and ssDNA template. 
Colonies from the plates undergo liquid selection before being plated again. The resulting edited colonies 





Table 2.1. Genome-wide non-synonymous mutations in protein coding sequence of Stm strains 
compared to their parent strains, identified by Next-Generation whole-genome sequencing. 
























233 A -> C TTG -> 
TGG 
L -> W SNP 
(transversion) 
Substitution 100.00% 






































Effects of acylation on HilA are site-specific 
 
With optimized CRISPR-Cas9 genome editing protocol in Salmonella, I first generated Stm strain 
with HA epitag at C-terminus of endogenous hilA gene. HA epitagging did not alter Stm growth 
(Fig. 2.8A), and gentamicin protection assay showed that Stm HilA-HA strain was similarly 
infective to HeLa cells compared to wild-type (Fig. 2.3B). Based on this Stm HilA-HA strain, I 
further edited amber codon (TAG) in place of individual lysine codons in the coding sequence of 
hilA in Stm genome. Stm HilA-K90TAG, HilA-K231TAG, HilA-K324TAG, HilA-K456TAG, and 
HilA-K533TAG mutants are to address the acylation effect on protein function, while Stm HilA-
K57TAG and Stm HilA-K527TAG mutants serve as loss-of-function and neutral control, 
respectively. I demonstrated that KBM could be efficiently incorporated into aforementioned 
amber codons at variable levels, respectively, as detected by both immunoblotting and in-gel 
fluorescence (Fig. 2.8B, 2.8C). 
 
To characterize the phenotype of endogenous, dominantly acylated HilA-KBM mutants, I first 
measured the expression level of a panel of SPI-1 genes (invF, prgH, sipA, orgB, spaO), which 
are directly or indirectly activated by HilA, through qRT-PCR (Fig. 2.8D). The lost-of-function 
mutation K57KBM on HilA caused decreased expression of SPI-1 genes as expected. The 
positive control HilA K527KBM had similar expression of SPI-1 genes compared to HilA-HA strain 
(wild type, WT). Interestingly, HilA-K90KBM, -K324KBM, and -K456KBM mutants had impaired 
expression of SPI-1 genes compared to WT, but not HilA-K231KBM or -K533KBM mutants. These 
differences were not due to mere different expression levels of each HilA mutant, as shown in Fig. 
2.8C. These results indicate that effects of acylation mimic on HilA are site-specific. 
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Figure 2.8. Effects of acylation on HilA are site-specific. (A) Growth curve of Stm 14028 WT and Stm 
14028 HilA-HA in SPI-1 inducing LB. (B) Total cell lysates of Stm HilA-HA and Stm HilA-KBM mutants were 
analyzed with anti-HA or anti-GroEL immunoblotting, and SDS-PAGE in-gel fluorescence scanning. (C) 
Relative expression level of HilA-KBM mutants compared to HilA-HA, quantified over 3 independent 
experiments of immunoblotting, with anti-GroEL as normalization control. (D) Expression of SPI-1 genes 
invF, prgH, sipA, orgB, and spaO was measured by qRT-PCR from Stm endogenous HilA K-to-KBM 
mutants. All mutants were compared to HilA-HA with one-way ANOVA and Dunnett post-test. *, P-value < 
0.05; **, P-value < 0.01; ***, P-value < 0.001. 
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Acylation at HilA K90 impacts HilA protein function 
Because K90 of HilA was predicted to be in its N-terminus DNA-binding domain (Fig. 2.3C, 2.3D), 
I hypothesized that the defect in expression of SPI-1 genes observed in K90KBM mutant was a 
result of impaired DNA-binding ability. To test this hypothesis, I performed ChIP-Seq on Stm HilA-
HA strain as well as Stm HilA-K90KBM-HA strain. Compared to HilA-HA, HilA-K90KBM-HA had 
decreased occupancy on promoter regions reported to be bound by HilA, including invF and prgH 
promoter regions (192) (Fig. 2.9A). K90KBM did not alter DNA binding specificity of HilA. This 
result was verified by ChIP-qPCR (Fig. 2.9B). HilA-K57KBM mutant, the negative control, 
occupied less at these promoter regions as well. Notably, HilA-K324KBM and -K456KBM mutants, 
which were defective in SPI-1 expression (Fig. 2.8D), had similar occupancy at these regions 
(Fig. 2.9B), suggesting that their defect in inducing SPI-1 expression are through alternative 
mechanism(s). Interestingly, HilA-K231KBM mutant has increased occupancy at invF and prgH 
promoter regions (Fig. 2.9B). These results suggest that decreased expression of SPI-1 genes 
in HilA-K90KBM mutant is the consequence of its defective DNA-binding activity. 
Acylation at specific sites of HilA impairs Salmonella virulence in vivo 
To further characterize virulence phenotype HilA K-to-KBM mutants, I assayed the infectivity of 
these mutants to HeLa cells. HilA-HA and K-to-KBM mutants were added to HeLa cell culture, 
and at 0.5 hour post-infection (hpi), gentamicin was added to kill extracellular Salmonella. 
Intracellular Stm were harvested 6 hpi and plated for CFU counting. HilA-K90KBM, -K324KBM, 
and -K456KBM mutants had impaired infectivity to HeLa cells compared to HilA-HA, while HilA-
K231KBM had slightly enhanced infectivity, and K533KBM mutants had similar infectivity to wild-
type. HilA-K57KBM and -K527KBM mutants served as loss-of-function control and positive control, 
respectively (Fig. 2.10A). These data corroborate with qRT-PCR data from these mutants, 




Figure 2.9. Acylation at HilA K90 impacts HilA DNA-binding activity. (A) HilA ChIP-Seq on Stm HilA-
HA and Stm HilA-K90KBM-HA. Reads Per Kilobase Million (RPKM) were shown in SPI-1 region. (B) ChIP-
qPCR on prgH promoter region (left) or invF promoter region (right) of Stm endogenous HilA K-to-KBM 
mutants. All mutants were compared to HilA-HA with one-way ANOVA and Dunnett post-test. *, P-value < 
0.05; **, P-value < 0.01. 
 
To further characterize virulence of HilA-K90KBM and -K231KBM mutants in vivo, we infected 
streptomycin-treated mice with 1x107 CFU of different Stm strains, respectively. Stm in both livers 
and mesenteric lymph nodes (mLN) of mice were harvested and plated at 48 hpi, and Stm 
bacterial loads in these two organs were measured by CFU counting. Stm HilA-HA strain 
disseminated to livers and mLN at a level similar to its parent strain Stm 14028S wild-type (Fig. 
2.10B). Stm HilA-K90KBM mutant was defective in systemic invasion, while K231KBM mutant 
behaved similarly to HilA-HA (Fig. 2.10C). These data suggest that HilA K90 acylated mutant has 
attenuated virulence in vivo, because of its defective expression of SPI-1 genes that are required 
for systemic infection. 
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Figure 2.10. Acylation at specific sites of HilA impairs Salmonella virulence in vivo. (A) Gentamicin 
protection assay of Stm endogenous HilA K-to-KBM mutants infecting HeLa cells at MOI=10. All mutants 
were compared to HilA-HA with one-way ANOVA and Dunnett post-test. *, P-value < 0.05; **, P-value < 
0.01; ***, P-value < 0.001. (B) Stm bacterial CFU counted from mesenteric lymph nodes (left) or liver (right) 
of mice 48 hpi infected with Stm WT or Stm HilA-HA. (C) Stm bacterial CFU counted from mesenteric lymph 
nodes (left) or liver (right) of mice 48 hpi infected with different Stm strains. K90KBM and K231KBM mutants 
were compared to HilA-HA with Kruscal-Wallis test and Dunns post-test. *, P-value < 0.05. (D) Scheme of 
SCFA inhibition on Stm virulence. Microbiota-derived SCFA could acylate Stm virulence regulator HilA at 
several lysine sites. K90, K324, and K456 acylation impact HilA function and reduce SPI-1 gene expression, 





While recent microbiome researches have demonstrated strong effects of microbiome on both 
host immunity and pathogen infection, underlying molecular mechanisms have just begun to be 
unveiled. In particular, SCFAs fermented by mammalian gut microbiota accumulate abundantly 
in the mammalian intestinal tract, and their effects on invading enteric pathogens and the 
underlying mechanisms have remained largely uncharacterized. 
 
The application of bio-orthogonal SCFA chemical reporter Alk-3 allows rapid and specific 
identification of molecular targets in pathogen proteome that are covalently modified by SCFAs. I 
demonstrated that Alk-3 behaves similarly to its natural counterpart SCFA in inhibiting virulence 
effector gene expression in Salmonella and its invasion in HeLa cells. Through CuAAC-mediated 
enrichment and mass spectrometry-based proteomics, I identified HilA, a key virulence 
transcriptional regulator, as a fatty-acylation target in Salmonella. I confirmed that HilA is acylated 
by both in-gel fluorescence scanning as well as Liquid Chromatography-tandem Mass 
Spectrometry (LC-MS/MS). While other SPI-1 related proteins were identified to be acylated by 
Alk-3 (Appendix 2.1), the pivotal role of HilA in SPI-1 leads us to investigate more on functional 
consequences of acylation on HilA. Interestingly, HilD, another key transcriptional regulator of 
SPI-1, which was suggested to be propionylated upon propionate incubation (71), was not found 
in our proteomics set. 
 
I found that acylation level on HilA was not affected in the presence of acyltransferase Pat or 
deacylase CobB. In fact, it is reported that CobB is less efficient in deacylation of propionyllysine 
and butyryllysine compared to that of acetyllysine (193). We surmised that short-chain acyl-CoA 
other than acetyl-CoA may not be optimal substrates for Pat, but short-chain acyl-phosphates are 
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similarly reactive to acetyl-phosphate, thus Pat cannot significantly change short-chain acylation 
level on protein. Similarly, acetylation, but not other short-chain acylation, can be readily removed 
by CobB. Besides, more deacylases yet to be discovered are suggested to be present in 
Salmonella (194–196), and HilA may not be the substrate for CobB, therefore I could not observe 
a drastic change in short-chain acylation level in the presence of CobB. 
 
After I confirmed HilA is acylated in vivo with both in-gel fluorescence scanning and LC-MS/MS, 
I seek to pinpoint the effects of acylation on HilA. CRISPR-Cas9 genome editing technique allows 
us to site-specifically edit codons of hilA gene in the Salmonella genome. The edited amber codon 
TAG enabled us to incorporate UAA to endogenously expressed HilA protein via amber 
suppression technology. Next-Generation Sequencing showed this genome editing approach had 
minimal off-target effect on other protein coding sequences.  In fact, these strains allow us not 
only to incorporate UAA bearing bio-orthogonal chemical group such as alkynyl group, but also 
to incorporate photo-cross-linking diazirine group to capture protein complex in vivo (Chapter 3). 
 
With Amber Suppression Technology, I could incorporate native or mimetic acyllysine to different 
sites of HilA. However, native acyllysines (including acetyllysine, propionyllysine, and 
butyryllysine) suffer from not only potential removal by endogenous deacylases, but also low 
incorporation efficiency. It is hard to interpret the defect in virulence when HilA native acyllysine 
mutants were expressed at significantly lower level than wild-type. Therefore, I incorporated KBM 
to study site-specific acylation effect on HilA. I found that acylation at K90, K324, and K456 affects 
expression of SPI-1 genes and impaired infectivity of Salmonella in HeLa cells. These different 
phenotypes cannot be explained by different expression level of these mutants. For example, 
HilA-K324KBM mutant was expressed at higher level than HilA-K533KBM, yet K324KBM was 




The DNA-binding domain of HilA is essential for its function, as deletion of this domain renders it 
not active in inducing SPI-1 expression (197). I also demonstrated that mutation to a key DNA-
interacting residue K57 also made the protein non-functional. Interestingly, K90 locates in the 
DBD of HilA. I showed that acylation at K90 affects the DNA-binding activity of HilA, yet K324KBM 
and K456KBM mutants, although attenuated in virulence, did not have defective DNA-binding 
activity. This suggest that acylation on HilA at different sites may alter function of the protein 
through various mechanisms. K324 and K456 locate in or near the predicted TPR domain of HilA, 
so it is possible that modification at these sites may affect interaction between HilA and its binding 
partners, for example, Salmonella RNA Polymerase (RNAP), and downregulate the transcription 
of SPI-1 genes. Another interesting observation is that HilAK231KBM mutant had slightly 
enhanced expression of SPI-1 genes and invasion in HeLa cells. Our in vivo photo-cross-linking 
data and protein size-exclusion chromatography data suggests that HilA may form homo-oligomer 
in vitro and in vivo, and K231 may be at the protein interface (Chapter 3). 
 
SCFA accumulate to very high concentration (more than 10 mM) in mammalian gut, but their 
concentration drops significantly when the gut undergoes inflammation, which causes microbiota 
dysbiosis (67). Our work reveals that Stm exploits SCFA as an important environmental cue for 
its opportunistic lifestyle. When gut microbiota is normal, Stm could settle in the gut without 
activating its virulence, utilizing SCFA as its energy source (198). However, when SCFA 
concentration drops greatly, indicating dysbiosis of microflora and removal of “colonization 
resistance”, Stm could remove PTM on HilA and activate its virulence, eliciting inflammation in 
the gut, which further benefit Stm survival in the gut (199), effectively causing a vicious cycle of 
infection. 
 
In summary, I applied bio-orthogonal SCFA reporter alk-3 to directly identify the biochemical 
targets of SCFA in Salmonella Typhimurium, and I found that exogenous SCFA can inhibit T3SS 
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of Stm and covalently modify key virulence transcriptional regulator HilA. By incorporation of bio-
orthogonal stable lysine acylation mimic site-specifically to endogenously expressed HilA in 
Salmonella, I revealed that fatty-acylation on K90, K324, and K456 of HilA impaired its function 
to activate virulence gene expression, and decreased Salmonella infectivity to HeLa cells (Fig. 
2.10D). In particular, acylation at K90 decreased HilA DNA-binding ability, making Stm less 
infective in mice. Our studies help elucidate fundamental mechanisms of microbiota-mediated 
resistance on bacterial virulence and should facilitate the development of new antibiotics and 
probiotics to treat bacterial infections. 
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Materials and Methods 
 
Microbial Strains and Growth Conditions 
All strains used are listed in Appendix Table 1. All Salmonella Typhimurium strains used were 
derivatives of S. Typhimurium 14028S (71). Salmonella strains were cultured at 37°C in liquid 
Miller Luria-Bertani (LB) medium [10 g/L tryptone, 5 g/L yeast extract, 10 g/L NaCl] (Becton 
Dickinson, DifcoTM), SPI-1 inducing LB medium [10 g/L tryptone, 5 g/L yeast extract, 300 mM 
NaCl], or on Salmonella Shigella agar (Becton Dickinson). Cultures were grown at 37°C in 
Multitron shaking incubator (INFORS HT) at 220 rpm. When required, antibiotics were added to 
the medium as follows: carbenicillin 100 μg/mL, kanamycin 50 μg/mL, and chloramphenicol 
10 μg/mL.  
 
Animal Experiments 
C57BL/6J (000664) mice were purchased from the Jackson Laboratory and maintained at the 
Rockefeller University animal facilities under SPF conditions. Animal care and experimentation 
were consistent with the National Institutes of Health guidelines and approved by the Institutional 
Animal Care and Use Committee of the Rockefeller University. 
 
Chemicals 
Sodium butyrate was purchased from Sigma-Aldrich (303410). Alk-3 (4-pentynoic acid) was 
purchased from Sigma-Aldrich (232211). Az-Rho was synthesized in the lab as previously 
described (164). Az-biotin was purchased from Sigma-Aldrich (762024). Acetyllysine was 
purchased from Sigma-Aldrich (A4021). Propionyllysine and butyryllysine were synthesized 
according to previously described (188). KBM was synthesized by Tao Peng according to 




Salmonella growth curve 
Overnight cultures of Salmonella strains in Miller LB were diluted 1:100 to 5 mL fresh SPI-1 
inducing LB medium in Falcon round-bottom 15 mL tubes. Cultures were taken out aliquots of 
750 uL from 0 hour to 5 hours at 1-hour interval. Aliquots were added to 10 mm polystyrene 
cuvettes (Sarstedt) and OD600 was measured with Biophotometer plus (Eppendorf).  
 
Preparation of Salmonella bacterial total cell lysates 
1:50 dilutions of overnight Miller LB cultures of Salmonella Typhimurium strain 14028 WT 
overnight culture were grown in 4 mL SPI-1 inducing LB for 4 h at 37°C with 220rpm shaking. For 
alk-3 labeling experiments, cultures were incubated with or without 10 mM fresh alk-3 (in dH2O). 
For incorporation of UAA into overexpressed HilA, cultures were added with 1 mM UAA and 0.2% 
arabinose. For incorporation of UAA into endogenous HilA, cultures were added with 100 uM UAA 
and 0.01% arabinose. S. Typhimurium cells were pelleted at 15000 g for 1 min, and pellets were 
lysed with 200 μL lysis buffer (phosphate-buffered saline (PBS) containing 0.5% Nonidet P-40, 
1X EDTA-free protease inhibitor cocktail (Roche), 0.5 mg/mL lysozyme (in dH2O) (Sigma), and 
1:1,000 dilution of Benzonase (Millipore)). After re-suspension, pellets were sonicated for 10 sec 
for 3 times, then were incubated on ice for 30 min. Cell lysates were centrifuged at 15000 g for 1 
min to remove cell debris and supernatants were collected. Protein concentration was estimated 
by BCA assay with BCA Protein Assay Kit (Thermo). 
 
Salmonella protein immunoprecipitation and immunoblotting 
From Salmonella total cell lysates prepared as described above, protein samples were boiled with 
1X Laemmli buffer 95°C for 5 min. 20 uL of each sample was loaded onto a 4-20% Tris-HCl gel 
(Bio-Rad) for SDS-PAGE. Proteins were transferred onto 0.45 μm nitrocellulose membrane (Bio-
Rad) with Trans-Blot Turbo Transfer System (Bio-Rad) at 25 V for 30 min. Membrane was blocked 
56 
 
with 5% non-fat milk in PBS with 0.1% Tween-20 (PBS-T) for 30 min, and primary antibody was 
added to solution before incubating membrane at 4°C overnight. Dilution of primary antibodies 
were as follows: for HA-tagged proteins, 1:2,000 anti-HA rabbit antibody H6908 (Sigma); for 
FLAG-tagged proteins, 1:2000 anti-FLAG rabbit antibody F7425 (Sigma); for HilA-K90Bu antigen, 
1:200 anti-HilAK90Bu rabbit custom antibody (Thermo Fisher) or 1:200 anti-HilAK90 rabbit 
custom antibody (Thermo Fisher). Membrane was washed with PBS-T 3 times, and incubated 
with 1:10,000 goat polyclonal anti-rabbit HRP ab97051 (Abcam) in PBS-T with 5% non-fat milk at 
room temperature for 1 hour. Membrane was washed with PBS-T 3 times, and imaged with Clarity 
Western ECL substrate (Bio-Rad) and ChemiDoc XRS+ System (Bio-Rad).    
For Salmonella protein immunoprecipitation, 250 μg of each total cell lysates were incubated with 
20 μL PBS-T-washed EZview™ Red Anti-HA Affinity Gel (Sigma) at 4 °C for 1 hour with end-to-
end rotation. Samples were washed with 200 μL PBS-T for 3 times, before being boiled with 1X 
Laemmli buffer 95°C for 5 min. 20 uL of each sample was loaded onto a 4-20% Tris-HCl gel (Bio-
Rad) for SDS-PAGE and further immunoblotting. 
 
In-gel fluorescence analysis of alk-3 labeling 
For in-gel fluorescence analysis of alk-3 labeled Salmonella proteome, from the alk-3-treated or 
control total cell lysates prepared as described above, 45 μL of each total cell lysates (~50 μg) 
was added with 5 μL of click chemistry reagents as a 10X master mix (az-Rho: 0.1 mM, 10 mM 
stock solution in DMSO; tris(2-carboxyethyl)phosphine hydrochloride (TCEP): 1 mM, 50 mM 
freshly prepared stock solution in dH2O; tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA): 
(0.1 mM, 2 mM stock in 4:1 t-butanol: DMSO); CuSO4 (1 mM, 50 mM freshly prepared stock in 
dH2O). Samples were mixed well and incubated at room temperature for 1 h. After incubation, 
samples were mixed with 200 μL cold methanol, 150 μL cold water, and 75 μL cold chloroform. 
Sample proteins were precipitated at 18000 g for 1 min at 4 °C. After gently removing the aqueous 
layer, protein pellets were washed with 200 μL cold methanol, spinning down at 18000 g for 1 min 
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at 4 °C, and liquid was gently decanted. After washing twice, pellets were allowed air-dried before 
boiling with 1X Laemmli buffer.   
For in-gel fluorescence analysis of alk-3 labeled HilA, from the alk-3-treated or control total cell 
lysates prepared as described above, 250 μg of each total cell lysates were immunoprecipitated 
with 20 μL PBS-T-washed EZview™ Red Anti-HA Affinity Gel (Sigma). After samples were 
washed with 200 μL PBS-T for 3 times, 36 μL of PBS was added to each sample. 4 μL of click 
chemistry reagents as a 10X master mix mentioned above were added to each sample. Samples 
were mixed well and incubated at room temperature for 1 h. After incubation, samples were 
washed with 200 μL PBS-T for 3 times.  
Samples were boiled with 1X Laemmli buffer 95°C for 5 min before being loaded onto a 4-20% 
Tris-HCl gel (Bio-Rad) for SDS-PAGE. In-gel fluorescence scanning was performed using a 
Typhoon 9400 imager (Amersham Biosciences). 
 
Alk-3 labeling Label-Free Quantitative proteomics 
1:50 dilutions of overnight Miller LB cultures of Salmonella Typhimurium strain 14028 WT 
overnight culture were grown in 20 mL SPI-1 inducing LB for 4 h at 37°C with 220rpm shaking, 
each sample growing in 4 mL aliquots. Cultures were incubated with or without 10 mM fresh alk-
3 (in dH2O). Cultures were pooled back to 20 mL per sample in Falcon tubes, and lysed in lysis 
buffer described above. After re-suspension in 1 mL lysis buffer, bacteria were sonicated for 15 
sec with Sonic Dismembrator Model 500 (Fisher Scientific) with 5 sec on and 10 sec off per cycle. 
Cell lysates were centrifuged at 15000 g for 1 min to remove cell debris and supernatants were 
collected. Each total cell lysates (~2 mg) was added with 100 μL of click chemistry reagents as a 
10X master mix (az-Biotin: 0.1 mM, 10 mM stock solution in DMSO; tris(2-carboxyethyl)phosphine 
hydrochloride (TCEP): 1 mM, 50 mM freshly prepared stock solution in dH2O; tris[(1-benzyl-1H-
1,2,3-triazol-4-yl)methyl]amine (TBTA): (0.1 mM, 2 mM stock in 4:1 t-butanol: DMSO); CuSO4 (1 
mM, 50 mM freshly prepared stock in dH2O). Samples were mixed well and incubated at room 
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temperature for 1 h. After incubation, samples were mixed with 4 mL cold methanol and incubated 
at -20°C overnight. Protein pellets were centrifuged at 5000 g for 30 min at 4°C, and were washed 
with 1 mL cold methanol 3 times. After last wash, pellets were let air dried before being re-
solubilized in 250 uL 4% SDS PBS with bath sonication. Solutions were diluted with 750 uL PBS, 
and incubated with 60 uL PBS-T-washed High Capacity NeutrAvidin agarose (Pierce) at room 
temperature for 1 h with end-to-end rotation. Agarose were washed with 500 uL 1% SDS PBS 3 
times, 500 uL 2M Urea PBS 3 times, and 500 uL PBS 3 times. Agarose were then reduced with 
100 uL 10 mM DTT (Sigma) in PBS for 30 min at 37°C, and alkylated with 100 uL 50 mM 
iodoacetamide (Sigma) in PBS for 20 min in dark. On-bead proteins were digested with 400 ng 
Trypsin/Lys-C mix (Promega) at 37°C overnight with shaking. Digested peptides were collected 
and lyophilized before being desalted with custom-made stage-tip containing Empore SPE 
Extraction Disk (3M). Peptides were eluted with 2% acetonitrile, 2% formic acid in dH2O.  
Peptide LC-MS analysis was performed with a Dionex 3000 nano-HPLC coupled to an Orbitrap 
XL mass spectrometer (Thermo Fisher). Peptide samples were pressure-loaded onto a home-
made C18 reverse-phase column (75 µm diameter, 15 cm length). A 180-minute gradient 
increasing from 95% buffer A (HPLC grade water with 0.1% formic acid) and 5% buffer B (HPLC 
grade acetonitrile with 0.1% formic acid) to 75% buffer B in 133 minutes was used at 200 nL/min. 
The Orbitrap XL was operated in top-8-CID-mode with MS spectra measured at a resolution of 
60,000@m/z 400. One full MS scan (300–2000 MW) was followed by three data-dependent scans 
of the nth most intense ions with dynamic exclusion enabled. Peptides fulfilling a Percolator 
calculated 1% false discovery rate (FDR) threshold were reported. 
Label-free quantification of alk-3 labeled proteins was performed with the label-free MaxLFQ 
algorithm in MaxQuant software as described (200). The search results from MaxQuant were 
analyzed by Perseus (http://www.perseusframework.org/). Briefly, the control replicates and alk-
3 labeled sample replicates were grouped correspondingly. The results were cleaned to filter off 
reverse hits and contaminants. Only proteins that were identified in all alk-3 labeled sample 
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replicates and with more than two unique peptides were subjected to subsequent statistical 
analysis. LFQ intensities were used for measuring protein abundance and logarithmized. Signals 
that were originally zero were imputed with random numbers from a normal distribution, whose 
mean and standard deviation were chosen to best simulate low abundance values below the 
noise level (Replace missing values by normal distribution – Width = 0.3; Shift = 2.2). Significant 
proteins that were more enriched in alk-3 labeled sample group versus control group were 
determined by a threshold strategy, which combined t test p-values with ratio information. Proteins 
with ratio larger than or equals to 2 and P-value smaller than 0.05 were categorized as hits. The 
resulting table was exported as Appendix 2.1. 
 
MS/MS detection of protein PTM 
1:50 dilutions of overnight Miller LB cultures of Salmonella Typhimurium strain 14028 hilA pBAD-
HilA-HA-His overnight culture were grown in 500 mL SPI-1 inducing LB with 10 mM sodium 
propionate or 10 mM sodium butyrate for 2 h at 37°C with 220rpm shaking, before 0.2% arabinose 
was added to induce HilA-HA-His expression for 3 h. Bacteria was harvested with 5000 g for 10 
min at 4°C, and lysed in 25 mL lysis buffer described above with 1 mM EDTA and 50 mM 
nicotinamide (NAM). bacteria were sonicated for 5 min with Sonic Dismembrator Model 500 
(Fisher Scientific) with 5 sec on and 10 sec off per cycle. Lysates were centrifuged at 5000 g for 
10 min at 4°C, and supernatants were filtered with 0.22 um filter before being loaded onto HisTrap 
FF 5mL column (GE Healthcare). HilA-HA-His protein was purified with wash with 3 Column 
Volume (CV) 100% buffer A (PBS-T, 50 mM NAM), wash with 5 CV 10% buffer B (PBS-T, 50 mM 
NAM, 300 mM imidazole), and 5 CV elution with gradient from 10% to 100% buffer B. Fractions 
containing HilA was pooled and dialyzed to PBS-T with 3 spin-dilution cycles in 10,000 MWCO 
filter (Amicon).  
Purified HilA-HA-His was immunoprecipitated with anti-butyryllysine antibody (PTM Biolab)- or 
anti-propionyllysine antibody (PTM Biolab)-conjugated protein A/G magnetic beads (Pierce), and 
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samples were boiled and run on SDS-PAGE. Coomassie Blue-stained bands corresponding to 
HilA was cut out, reduced with 10 mM DTT (Sigma) in fresh 100 mM ammonium bicarbonate 
(ABC) for 30 min at 37°C, and alkylated with 50 mM iodoacetamide (Sigma) in fresh 100 mM ABC 
for 20 min in dark. Gel pieces were digested with 200 ng Trypsin/Lys-C mix (Promega) at 37°C 
overnight with shaking.  
 
Salmonella CRISPR-Cas9 genome editing 
To make electrocompetent Salmonella Typhimurium, overnight culture of Salmonella 
Typhimurium strains were diluted 1:50 to 100 mL fresh LB, and were grown at 37°C in shaking 
incubator at 220 rpm for 2 hours, until OD600 reached 0.5 to 0.7. Cells were pelleted at 5000 g for 
10 min at 4°C, and washed with 50 mL ice-cold 10% glycerol twice. Cell pellets were resuspended 
in 500 uL 10% glycerol, and aliquoted 50 uL per tube.   
Electrocompetent parent Salmonella Typhimurium strains were transformed with pKD46 via 
electroporation with Gene Pulser II (Bio-Rad) at 2.5 kV and 25 uF in 2 mm cuvette, and selected 
on Ampicillin agar plates at 30 °C overnight. The resulting Salmonella Typhimurium pKD46 strains 
were made into electrocompetent cells after grown at 30°C with 0.2% arabinose and ampicillin. 
Salmonella Typhimurium pKD46 electrocompetent cells were transformed with 2 uL pWJ297-
sgRNA (~100 ng) and 10 uL 10 uM ssDNA editing template and selected on Chloramphenicol 
agar plates at 37 °C overnight. All colonies on the plate were collected with cell scraper and 
resuspended in 4 mL LB with Chloramphenicol. The bacterial suspension were diluted 1:50 to 4 
mL fresh LB with Chloramphenicol, and were grown at 37°C in Multitron shaking incubator 
(INFORS HT) at 220 rpm for 2 hours. Culture was streaked onto Chloramphenicol agar plates, 
and colonies from the plates were randomly picked for colony PCR to confirm successful editing. 
Successfully edited colonies were streaked onto plain agar plates to cure pWJ297-sgRNA, and 




Salmonella whole-genome sequencing 
1 mL of Salmonella cultures were processed with Quick-DNA Fungal/Bacterial kit (Zymo 
Research) per manufacturer’s manual. Purified Salmonella genomes were sent to Rockefeller 
University Genomics Center for processing with Nextera XT gDNA library preparation and 
sequencing with MiSeq 75 Pair-End sequencing. Sequencing results were analyzed with 
Geneious software.  
 
Salmonella Quantitative Reverse-Transcription PCR 
500 uL of Salmonella cultures were processed with RNeasy Mini Kit (Qiagen) per manufacturer’s 
manual. Concentrations of purified RNA were normalized to 100 ng/uL with RNase-free water. 
Quantitative Reverse-Transcription PCR (qRT-PCR) were performed with Power SYBR Green 
RNA-to-CT 1-Step Kit (Applied Biosystems) per manufacturer’s manual and primers listed in 
Appendix Table 2.  
 
Salmonella HilA ChIP-qPCR and ChIP-seq 
4 mL Salmonella cultures were crosslinked with 1% methanol-free PFA (Thermo) for 20 min at 
room temperature. Crosslinking were quenched with 125 mM Glycine (Fisher). Bacteria were 
centrifuged 16000 g at 4°C for 1 min and washed with 1 mL PBS twice. Pellets were resuspended 
in 500 uL ChIP Lysis Buffer (10 mM Tris-HCl, pH 8.0, 20% sucrose, 50 mM NaCl, 10 mM EDTA, 
10 mg/mL lysozyme), and incubated at 37°C for 30 min. Lysates were added with 500 uL 2X RIPA 
buffer (100 mM Tris-HCl, pH 8.0, 300 mM NaCl, 2% Nonidet P-40 (NP-40), 1% sodium 
deoxycholate, 0.2% SDS) and sonicated with Sonic Dismembrator Model 500 (Fisher Scientific) 
for 10 sec. Resulting solutions were centrifuged at 16000 g for 1 min at room temperature. 100 
uL supernatants were saved as total inputs. 750 uL of the remaining supernatants of each were 
incubated with 2 uL anti-HA ChIP-grade polyclonal antibody (ab9110, Abcam) at 4°C for 1 h with 
end-to-end rotation. The solutions were then added to 30 uL PBS-T-washed protein A/G magnetic 
62 
 
beads (Pierce) and incubated at 4°C for 1 h with end-to-end rotation. Beads were washed with 
500 uL 1X RIPA buffer twice, 500 uL LiCl Wash buffer (10 mM Tris-HCl, pH 8.0, 250 mM LiCl, 1 
mM EDTA, 0.5% NP-40, 0.5% sodium deoxycholate) twice, and 500 uL Tris-EDTA buffer (10 mM 
Tris-HCl, pH 8.0, 1 mM EDTA) once. Samples were eluted with 100 uL SDS Elution buffer (50 
mM Tris-HCl, pH 8.0, 10 mM EDTA, 1% SDS) at 65°C for 10 min. Each total input sample and 
ChIP sample were added with 5 uL 20 mg/mL proteinase K (Qiagen) and de-crosslinked at 65°C 
overnight. All de-crosslinked samples were purified with E.Z.N.A. Cycle Pure kit (Omega Bio-tek) 
and eluted with 100 uL elution buffer in the kit. ChIP-qPCR were performed with PowerUp SYBR 
Green Master Mix (Applied Biosystems) per manufacturer’s manual. Same samples were sent to 
Rockefeller University Genomics Center for library preparation and sequenced with NextSeq High 
Output 75 Single-Read sequencing. 
 
In vitro invasion assay and intracellular survival assay 
HeLa cells were cultured in 12-well tissue culture plates at 80-90% confluency. Wells were added 
with Salmonella cells at an MOI = 10:1 and centrifuged at 1000 g for 5 min. Cells were incubated 
at 37°C with 5% CO2 for 30 min to allow invasion. The media was then replaced with medium 
containing 100 μg/mL gentamicin and incubated for an additional hour to kill extracellular 
Salmonella. Wells were then washed 3 times with PBS, and cells were lysed with 500 uL 1% 
Triton X-100 PBS. Lysates were serially diluted and drip-dropped on Salmonella Shigella agar 
plates (BD 211597) to determine the number of invaded bacteria. 
For intracellular survival assay of Salmonella, after incubation with medium containing 100 μg/mL 
gentamicin for 1 h, media was replaced with medium containing 10 μg/mL gentamicin and 
incubated for additional 4.5 hours at 37°C, 5% CO2. Intracellular bacterial counts were obtained 
by lysing cells and drip-dropping serial dilutions on Salmonella Shigella agar plates.  
 
S. Typhimurium infection of mice 
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To ensure effective colonization and induce infection susceptibility, SPF mice were gavaged with 
a single dose of 20 mg of streptomycin 24 hours before infection. Bacterial cultures of different S. 
Typhimurium strains were washed and re-suspended in sterile phosphate-buffered saline (PBS) 
at 107 CFU/mL. Mice were gavaged with 100 μL of the bacterial suspension. Leftover inocula were 
serially diluted and plated to confirm the number of CFU administered. 
For 48 h infection experiments, mice were euthanized 48 hours after S. Typhimurium gavage. 
Colony-forming units (CFU) in the livers and mesenteric lymph nodes (mLN) were determined by 
plating five serial dilutions of livers or mLN suspended in sterile 0.1% Triton X-100 PBS on 
Salmonella Shigella agar (BD 211597). Resulting quantities were normalized to liver or mLN 
weight.  
For S. Typhimurium infection survival assay, mice weight loss was monitored just before infection, 
and mice were euthanized when they reached 80% baseline weight, appeared hunched or 
moribund, or exhibited a visibly distended abdomen (indicative of peritoneal effusion), whichever 
occurred first. Death was not used as an end point. Colony-forming units (CFU) in the feces were 
determined by plating five serial dilutions of feces suspended in sterile PBS on Salmonella 
Shigella agar (BD 211597). Resulting quantities were normalized to fecal weight.  
 
Quantification and Statistical Analysis 
Comparisons and statistical tests were performed as indicated in each figure legend. Briefly, 
Pairwise comparisons were generated with two-tailed t tests. For comparisons of multiple groups 
over time or with two variables, a two-way analysis of variance (ANOVA) was used with an 
appropriate Bonferroni posttest comparing all groups to each other, all groups to a control, or 
selected groups to each other. Survival data were analyzed using a log-rank (Mantel-Cox) test 
with a Bonferroni correction for the degrees of freedom based on the number of comparisons 
made. To compare two groups with non-normal distribution or low sample size, the medians of 
the two groups were compared using a Mann-Whitney test, unless one data set contained only 
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zero values. In these cases, a Mann-Whitney test could not be performed because all values in 
the group were identical; a Wilcoxon test was performed instead. For comparisons of multiple 
groups with only one variable, a one-way ANOVA or Kruskal-Wallis test was performed for data 
with underlying normal or non-normal distribution, respectively, with Bonferroni, Dunnett’s, or 
Dunn’s posttests where appropriate. Statistical analyses were performed in GraphPad Prism 
software. A P value of less than 0.05 was considered significant, denoted as *P ≤ 0.05, **P ≤ 0.01, 












Effects of diet-derived long-chain fatty acids on Salmonella  
and 






Fatty acids, especially long-chain fatty acids (LCFA) derived from the diet, have been shown to 
inhibit key bacterial virulence pathways, such as type III secretion system (T3SS) in Gram-
negative enteric bacterial pathogens, but the molecular mechanism(s) are still under investigation. 
I found that fatty acids of different carbon chain length had different inhibitory efficacy on 
Salmonella Pathogenicity Island-1 T3SS, and fatty acids with longer chain were more potent. We 
applied bio-orthogonal alkyne-fatty acid reporters to directly identify the biochemical targets of 
LCFA in Salmonella Typhimurium. With in-gel fluorescence profiling, click chemistry-mediated 
enrichment and mass spectrometry-based proteomics, I found that exogenous LCFA could 
covalently modify key virulence transcriptional regulator HilA. With a different LCFA chemical 
reporter and hydroxylamine treatment, I demonstrated that the modification is a bona fide post-
translational N-long-chain fatty acylation. The modification on HilA was not susceptible to 
enzymatic acylation or deacylation mediated by Pat and CobB. Mutating individual potential 
acylated lysine residues to alanine in HilA could not abolish LCFA labeling on HilA. Moreover, via 
Amber Suppression Technology, a photo-crosslinking unnatural amino acid was incorporated in 
place of key lysine residues in endogenous HilA in vivo, and it revealed that HilA forms oligomers 
in Salmonella, with K231 at potential protein interaction interface. These studies elucidate 
fundamental mechanisms of diet-mediated resistance against Salmonella infection and should 








S. enterica is a Gram-negative intracellular pathogen that causes gastroenteritis and typhoid fever 
worldwide (159). Once ingested, Salmonella traverses the gut to the small intestine, where a set 
of virulence genes are activated to promote gut inflammation as well as invasion of the intestinal 
epithelia, allowing Salmonella to replicate and disseminate throughout the host (160). Systemic 
infection associated with typhoid fever is mediated by two Salmonella pathogenicity islands (SPI) 
that encode Type 3 Secretion Systems (T3SS) for bacterial invasion, dissemination, and 
replication inside host cells (159, 160). Specifically, SPI-1 is important for Salmonella invasion, 
while SPI-2 is crucial for Salmonella replication in host cells (161). Genetic and biochemical 
studies have demonstrated that T3SS form multi-protein complexes to inject a variety of bacterial 
protein effectors into host cells for Salmonella pathogenesis (159, 160).  
 
Of note, medium-chain fatty acids (MCFA) and long-chain fatty acids (LCFA) from the diet have 
been shown to inhibit Salmonella enterica serovar Typhimurium (Stm) virulence and colonization 
(201, 202). Unsaturated LCFA are shown to act as input signals for PhoP/PhoQ two-component 
regulatory system, and inhibit PhoP-dependent regulon, including SPI-1 (203). LCFA have been 
implicated in inhibiting Salmonella virulence through non-covalent interaction with SPI-1 
transcription regulator HilD (204), but whether LCFA may affect Salmonella virulence through 
other molecular mechanism(s) remains to be studied. Understanding the effects of long-chain 
fatty acids on Stm will help elucidate the interactions between host, commensal bacteria, and 




In this chapter, I demonstrate that HilA, a key virulence regulator of SPI-1 T3SS in Stm, is long-
chain fatty-acylated using long-chain fatty acid chemical reporter alk-16. The modification is post-
translational and attached to amine group on the protein. Moreover, using site-specific 
incorporation of photo-crosslinking unnatural amino acid, I provided evidence that HilA forms 






Long-chain fatty acids inhibit Salmonella virulence 
 
Beyond my studies with butyrate in Chapter 2, I observed that fatty acids of different carbon chain 
length could inhibit Salmonella secretion in vitro (Fig. 3.1A). For example, SCFA butyrate (C-4) 
inhibited Salmonella SPI-1 secretion at 10 mM; medium-chain fatty acids, caprylic acid (C-8) and 
lauric acid (C-12), inhibited secretion at 500 uM; LCFA palmitic acid (C-16) could significantly 
inhibit Salmonella secretion at 100 uM. Of note, in mammalian gut, C-16 concentrations could 
reach to about 400 uM (205). The half maximal inhibitory concentrations (IC50) of each tested fatty 
acids were estimated based on secretion assay, and were plotted on Fig. 3.1B. Longer chain 
length of fatty acids was correlated with stronger potency in Stm T3SS inhibition. This inhibitory 
effect was not due to inhibition of bacterial growth, as measured by OD600 (data not shown). C-16 
at 100 uM decreased Stm invasion ability to HeLa cells (Fig. 3.1C), and inhibited expression level 
of Stm SPI-1 effector genes such as sipA, as shown by quantitative reverse–transcription PCR 
(qRT-PCR) (Fig. 3.1D). This suggest that C-16 inhibits Stm virulence through antagonizing 
transcription and expression of Stm SPI-1 effector proteins. 
 
Proteomic analysis of long-chain fatty acylated proteins in Salmonella 
 
To identify long-chain fatty acylated proteins in Salmonella, I employed LCFA chemical reporter 
alk-16 (17-octadecynoic acid) (Fig. 3.2A). Alk-16 behaved similarly to its natural counterpart C-
16, as it retained the ability to inhibit Stm invasion to HeLa cells (Fig. 3.2B). To visualize long-
chain fatty acylated proteins with alk-16, I incubated Stm culture with 100 uM alk-16, and 
harvested total cell lysates for CuAAC reaction with azide-functionalized Rhodamine (az-Rho, Fig. 
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2.2A). SDS-PAGE followed by in-gel fluorescence scanning demonstrated that alk-16 
metabolically labeled a diverse repertoire of proteins in Stm (Fig. 3.2C). To identify these long-
chain fatty acylated proteins, I performed Label-Free Quantitative (LFQ) Proteomics analysis on 
Stm proteome with or without alk-16 labeling. Stm cell lysates were reacted with an azido-biotin 
affinity tag (az-biotin, Fig. 2.2B). Alk-16 labeled proteins were enriched by streptavidin beads, 
and digested by Trypsin/LysC mix on-bead. Digested peptides were processed and identified by 
Liquid Chromatography–tandem Mass Spectrometry (LC-MS/MS). The resulting spectrum were 
searched with MaxQuant (176) and quantified with Perseus (177). 
 
Figure 3.1. Long-chain fatty acids inhibit Salmonella virulence. (A) Salmonella secretion assay of 
different fatty acids. Salmonella was grown in LB in the presence of indicated concentration of different fatty 
acids, and secreted proteins in supernatants were precipitated with TCA and analyzed on SDS-PAGE. 
Identity of secreted protein bands are labeled on the right, with SPI-1 proteins colored in red. (B) IC50 of 
different saturated fatty acids on Salmonella SPI-1 secretion, estimated by secretion assay. (C) Gentamicin 
protection assay of Stm incubated with or without 100 uM C-16 infecting HeLa cells at MOI=10. (D) 





I identified ‘hits’ as proteins qualified for criteria of FDR = 0.05 and S0=2 in Perseus. With this 
approach, I identified 236 proteins labeled by alk-16 compared to control samples (Fig. 3.2D, 
Appendix 3.1). Of all the hits identified, 59% were categorized as metabolism-related proteins 
(Fig. 3.2E). Moreover, 9 proteins in these hits (3.8%) were directly related to Stm virulence (Fig. 
3.2D, Appendix 3.1). Notably, HilA, a master transcriptional activator of Stm SPI-1 virulence (178, 
179), was present in the hit set. 
 
Figure 3.2. Proteomic analysis of long-chain fatty acylated proteins in Salmonella. (A) Molecular 
structure of palmitic acid (C-16) and Alk-16. (B) Gentamicin protection assay of Stm incubated with or 
without 100 uM alk-16 infecting HeLa cells at MOI=10. (C) Salmonella cell lysates were reacted with az-
Rho by CuACC, and proteins were separated by SDS-PAGE for visualization by fluorescence gel scanning 
(top). Coomassie blue staining demonstrates comparable loading (bottom). (D) Salmonella cell lysates were 
reacted with az-biotin by CuAAC for the enrichment of alk-16–labeled proteins with streptavidin beads and 
identification by mass spectrometry. LFQ proteomic analysis Identified proteins that were enriched by alk-
16 (top right corner above threshold line). Four selected SPI-1 proteins are labeled and colored in red. (E) 
Pie chart of annotated functions of alk-16 enriched proteins.  
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HilA is N-long-chain fatty acylated in Salmonella 
 
As shown in Chapter 2, HilA is a master transcription regulator of SPI-1 that is essential for 
Salmonella virulence. To confirm that HilA was indeed long-chain fatty acylated, Stm 
overexpressing HilA-HA-His6 was grown in medium with alk-16, and CuAAC in-gel fluorescence 
scanning of cell lysates demonstrated that HilA was labeled by alk-16 (Fig. 3.3A). LCFA could be 
broken down to shorter-chain fatty acids in Salmonella through -oxidation pathway (206), thus 
the fluorescence signal detected on HilA with alk-16 does not necessarily demonstrate long-chain 
fatty acylation on HilA. Therefore, we decided to employ another LCFA chemical reporter, HDYOA 
(15-hexadecynyloxyacetic acid, Fig. 3.3B) (207). HDYOA is structurally similar to alk-16, except 
that oxygen substitutes for carbon at beta position of the carboxyl group. This renders HDYOA 
resistant to -oxidation, yet HDYOA could still label similar sets of palmitoylated proteins 
compared to alk-16 in vivo (207). HDYOA also readily labeled HilA (Fig. 3.3A), suggesting that 
HilA was indeed long-chain fatty acylated.  
To confirm that HilA is modified post-translationally, we used a combination of antibiotics (rifampin, 
streptomycin, and spectinomycin) to stop the protein translation in Stm before adding alk-16 for 
protein labeling. HilA was still readily labeled by alk-16 (Fig. 3.3C), suggesting that long-chain 
fatty acylation on HilA is a bona fide post-translational modification. To investigate whether 
acylation on HilA is regulated by acyltransferase and deacylase in Salmonella, HilA-HA-His6 was 
co-expressed with Gcn5-like Protein Acyltransferase (Pat), or the only known protein deacylase 
in Salmonella, CobB. CuAAC in-gel fluorescence scanning showed that while Pat increased and 
CobB decreased alk-16 labeling level on Salmonella proteome (Fig. 3.3D), alk-16 labeling level 












Figure 3.3.  HilA is N-long-chain fatty acylated in Salmonella. (A) Stm overexpressing HilA-HA-His were 
incubated with DMSO, 100 uM alk-16, or 100 uM HDYOA before CuAAC with az-Rho, SDS-PAGE in-gel 
fluorescence scanning (top), and immunoblotting (bottom). (B) Molecular structure of HDYOA. (C) Stm 
overexpressing HilA-HA-His were incubated with or with antibiotic cocktail (ABX), before DMSO or 100 uM 
alk-16 were added. Cell lysates were reacted through CuAAC with az-Rho, followed by SDS-PAGE in-gel 
fluorescence scanning (top), and immunoblotting (bottom). (D)(E) Salmonella overexpressing HilA-HA-His, 
as well as Pat-Flag or CobB-Flag, were incubated with or without alk-16 during overexpression. Total cell 
lysates (D) and anti-HA immunoprecipitated samples (E) were analyzed with SDS-PAGE in-gel 
fluorescence scanning (top), and anti-Flag (D) or anti-HA (E) immunoblotting (bottom). (F) Stm 
overexpressing HilA-HA-His were incubated with 100 uM alk-16 and treated with or without NH2OH, before 
CuAAC with az-Rho, SDS-PAGE in-gel fluorescence scanning (top), and immunoblotting (bottom). (G) Stm 
overexpressing different HilA K-toA mutants were incubated with DMSO or 100 uM alk-16, before CuAAC 
with az-Rho, SDS-PAGE in-gel fluorescence scanning (top), and immunoblotting (middle). The secreted 
SPI-1 effector proteins were precipitated from supernatant with trichloroacetic acid and run on SDS-PAGE, 








Long-chain fatty acylation could happen on various residues on proteins. For example, S-
palmitoylation is a post-translational modification on cysteine residues, and dynamic modification 
on different cysteines could affect protein localization and function in mammalian cells (163, 208). 
S-stearoylation of TFR1 regulates its activation of JNK signaling and mitochondrial function in 
Drosophila (209). Long-chain fatty acylation may also happen on lysine residues, which could 
regulate protein secretion (210). S-long-chain fatty acylation is sensitive to hydroxylamine 
treatment, while N-long-chain fatty acylation would be resistant. I showed that alk-16 labeling on 
HilA was not sensitive to hydroxylamine treatment (Fig. 3.3F), which indicates that alk-16 
modification on HilA is N-long-chain fatty acylation.      
 
In Chapter 2, I have identified 5 lysine residues in HilA that could be short-chain fatty acylated. 
We hypothesized that these same lysine residues may also be residues for long-chain fatty 
acylation. Alanine mutation would abolish post-translational modification on the lysine residue, 
therefore I made individual K-to-A HilA mutants, namely K90A, K231A, K324A, K456A, and 
K533A, as well as K57A as a control. All mutants except K57A mutant were functional when over-
expressed as they could rescue SPI-1 secretion in Stm hilA mutant (Fig. 3.3G). However, all 
mutants were still labeled by alk-16 (Fig. 3.3G), suggesting that long-chain fatty acylation may be 
on multiple lysine residues of HilA. These results suggest that LCFA may attenuate Salmonella 
virulence also through direct fatty acylation of proteins, including HilA and other SPI-1 factors, 
which remains to be further characterized.  
 
HilA forms oligomers in Salmonella  
 
In Chapter 2, I have shown that when K231 is dominantly acylated through incorporation of KBM, 
Stm has elevated SPI-1 expression and enhanced invasion ability to HeLa cells. Since HilA is a 
transcription activator, which presumably recruits RNA polymerase complex during transcription 
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initiation, we hypothesized that K231 of HilA may be important for protein-protein interaction. To 
explore whether HilA has interacting protein partners in vivo, we decided to use Amber 
Suppression Technology to incorporate an unnatural amino acid with photo-crosslinking 
functional group. DiZPK (3-(3-methyl-3H-diazirin-3-yl)-propamino-carbonyl-Nε-L-Lysine) UAA 
(Fig. 3.4A) is developed to be site-specifically incorporated in proteins-of-interest to capture their 
interacting protein partners in vivo (211), including in Salmonella (212). The diazirine group at the 
side chain of DiZPK, when irradiated with 365 nm UV light, would form a highly reactive carbene 
group, crosslinking any nearby interacting molecules. This enables covalently capturing 
interacting partners with transient interactions at different conditions in vivo.  
With endogenous amber mutants in hand, I incorporated DiZPK into K90, K231, K324, K456, 
K533, K57, and K527 of endogenous HilA, and photo-cross-linked in vivo with 365 nm UV light 
for 5 min. Interestingly, HilA-K231DiZPK crosslinked unknown partner(s) and formed a complex 
with apparent molecular weight about 200 kDa (Fig. 3.4B). Interestingly, K90DiZPK and 
K527DiZPK mutant also crosslinked unknown partner(s) and formed higher-molecular-weight 
complex. This photo-crosslinking was both site-specific and UV-dependent, as other HilA K-to-
DiZPK mutants did not cross-link similar complex, nor did HilA-K231DiZPK, -K90DiZPK, or -
K527DiZPK without UV treatment (Fig. 3.4B). I then set out to identify what interacting protein(s) 
HilA-K231DiZPK captured. We performed a large-scale photo-cross-linking with 
immunoprecipitation enrichment for HilA and its crosslinked complex, and cut out protein-complex 
gel bands and corresponding regions in no-UV-treatment samples in SDS-PAGE (Fig. 3.4C). 
These gel bands were digested with Trypsin/LysC mix and processed for LFQ proteomic analysis. 
Surprisingly, HilA was the only protein identified in the protein complex (Fig. 3.4D). Moreover, 
size-exclusion chromatography (SEC) showed that purified HilA eluted at fractions that 
corresponds to ~200 kDa molecular weight proteins, indicating HilA formed oligomers in vitro (Fig. 
3.4E). These data suggest that HilA forms homo-oligomer in vivo, and K231 is at the interface 
between monomers. We are actively pursuing to elucidate atomic structure of HilA through X-ray 
crystallography. We have obtained some protein crystals of HilA through screening (Fig. 3.4F), 
and X-ray diffraction data acquisition as well as data analysis will be performed in collaboration 



















Figure 3.4. HilA forms oligomers in Salmonella. (A) Molecular structure of DiZPK. (B) Anti-HA 
immunoblotting of different HilA-HA amber codon mutants with or without DiZPK, and with or without UV 
cross-linking treatment. (C) Coomassie Blue stained SDS-PAGE gel of large-scale anti-HA 
immunoprecipitated HilA-K231DiZPK samples with or without UV treatment. Red dashed boxes indicate 
gel regions cut out for protease digestion and LFQ proteomics. (D) Volcano plot of HilAK231DiZPK photo-
cross-linking LFQ proteomics. Vertical blue dashed lines indicate 2-fold difference between two sets of 
samples; horizontal blue dashed line indicates P-value=0.05. (E) SEC chromatogram of affinity purified HilA. 
Estimated molecular weight of each peak and its identity was labeled. (F) Brightfield and UV channel photos 












Recent studies on host-microbe interactions have elucidated that environmental factors have 
significant impact on both host immunity and pathogen infection, but underlying molecular 
mechanisms have just begun to be unveiled. In particular, LCFAs derived from diet accumulate 
abundantly in the mammalian intestinal tract, and their effects on invading enteric pathogens and 
the underlying mechanisms have remained largely uncharacterized. 
 
I have shown that fatty acids of different chain length have different potency in inhibiting 
Salmonella T3SS, and long-chain fatty acids are most effective. Of note, palmitic acid inhibit 
Salmonella SPI-1 secretion efficiently at 100 uM. While medium-chain fatty acids (7–12 carbon 
fatty acids) are present naturally in food, their concentrations in mammalian gut remain elusive. 
Long-chain fatty acids, e.g. palmitic acid, are abundant in both animal and vegetarian fat, and 
their concentrations accumulates to hundreds micromolar range in the gut (205). This raises the 
question how Salmonella cope with the combination of tens millimolar SCFA and hundreds 
micromolar LCFA, both of which are inhibitory on Salmonella virulence. A coordinate and 
centralized response to fluctuation of both SCFA and LCFA concentrations would be an efficient 
approach for Salmonella to switch itself between virulent and avirulent phenotype.    
 
The application of bio-orthogonal LCFA chemical reporter Alk-16 allows rapid and specific 
identification of molecular targets in pathogen proteome that are covalently modified by LCFAs 
(164). I demonstrated that Alk-16 behaves similarly to its natural counterpart LCFA in inhibiting 
Salmonella invasion in HeLa cells. Through CuAAC-mediated enrichment and mass 
spectrometry-based proteomics, I identified HilA, a key virulence transcriptional regulator, as a 
fatty-acylation target in Salmonella. I confirmed that HilA is long-chain fatty acylated by in-gel 
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fluorescence scanning. Direct detection of long-chain fatty acylation on proteins by Liquid 
Chromatography-tandem Mass Spectrometry (LC-MS/MS) has been a technical challenge, 
requiring extensive optimization on sample preparation, LC condition, and data acquisition 
(Thinon E. et al., unpublished). Interestingly, HilD, another key transcriptional regulator of SPI-1, 
which was suggested to be inhibited by LCFA through non-covalent interaction (204), was not 
found in our proteomics set. Indeed, our method could only detect proteins covalently labeled by 
alk-16. A bi-functional LCFA, containing both photo-crosslinking and alkyne groups, would enable 
capture of non-covalent interacting proteins with LCFA (213). 
 
I found that long-chain fatty acylation on HilA was a bona fide post-translational N-acylation. While 
long-chain fatty acylations, both S- and N-linked, have been studied extensively in eukaryotes 
(163, 210, 214), their presence on bacterial proteins has been less studied. Previous report 
suggests the presence of S-long-chain acylation on E. coli protein YjgF, as the modification is 
abolished by cysteine-to-serine mutation (164). Lysine long-chain fatty acylation is also reported 
on E. coli hemolysin, which is required for its toxic activity (215). N-long-chain fatty acylation may 
occur on multiple lysine residues of HilA, and identification of exact modification sites would 
facilitate downstream studies on effects of long-chain fatty acylation on HilA function. Hang lab is 
currently developing a new isotopic cleavable affinity tag for direct identification of PTM sites 
(Tsukidate T et al., unpublished), which may help identification of long-chain fatty acylation sites 
on HilA.  
 
To study protein-protein interaction between HilA and its partners, I have incorporated photo-
crosslinking DiZPK to endogenous HilA. I found that K231 and K527 could photo-crosslink 
interacting protein partner(s). K231 is identified to be short-chain fatty acylated (Chapter 2), while 
K527 is not reported to have significant functional role in HilA. Structural studies might help explain 
where these two lysine residues reside spatially in the protein, and how they might contribute to 
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protein-protein interaction. Surprisingly, through LFQ proteomics analysis, we found that HilA-
K231DiZPK photo-crosslinked itself but not other proteins in vivo. SEC of purified HilA also 
demonstrated oligomerization of HilA in vitro. It would be interesting to see if HilA crystal is packed 
in oligomer form, which may reveal information about protein-protein interaction interface. 
 
In summary, I applied bio-orthogonal LCFA reporter alk-16 to directly identify long-chain fatty 
acylated proteins in Salmonella Typhimurium, and I found that exogenous LCFA can inhibit T3SS 
of Stm and covalently modify key virulence transcriptional regulator HilA. The post-translational 
N-long-chain fatty acylation may contribute to inhibitory effect of LCFA on Salmonella virulence. 
Moreover, photo-crosslinking studies reveal that K231 and K527 may contribute to HilA interaction 
with other proteins, and K231 may be at the interface of HilA homo-oligomers. Our studies help 
elucidate fundamental mechanisms of diet-mediated resistance on bacterial virulence and should 
facilitate the development of new approaches to treat bacterial infections. 
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Materials and Methods 
 
Microbial Strains and Growth Conditions 
All strains used are listed in Appendix Table 1. All Salmonella Typhimurium strains used were 
derivatives of S. Typhimurium 14028S (14). Salmonella strains were cultured at 37°C in liquid 
Miller Luria-Bertani (LB) medium [10 g/L tryptone, 5 g/L yeast extract, 10 g/L NaCl] (Becton 
Dickinson, DifcoTM), SPI-1 inducing LB medium [10 g/L tryptone, 5 g/L yeast extract, 300 mM 
NaCl], or on Salmonella Shigella agar (Becton Dickinson). Cultures were grown at 37°C in 
Multitron shaking incubator (INFORS HT) at 220 rpm. When required, antibiotics were added to 




Alk-16 (17-Octadecynoic Acid) was synthesized according to previously described (216). Az-Rho 
was synthesized in the lab as previously described (17). Az-biotin was purchased from Sigma-
Aldrich (762024). DiZPK was synthesized according to previously described (217). 
 
Preparation of Salmonella bacterial total cell lysates 
1:50 dilutions of overnight Miller LB cultures of Salmonella Typhimurium strain 14028 WT 
overnight culture were grown in 4 mL SPI-1 inducing LB for 4 h at 37°C with 220rpm shaking. For 
alk-16 labeling experiments, cultures were incubated with or without 10 mM fresh alk-16 (in 
DMSO). For incorporation of UAA into overexpressed HilA, cultures were added with 1 mM UAA 
and 0.2% arabinose. For incorporation of UAA into endogenous HilA, cultures were added with 
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100 uM UAA and 0.01% arabinose. S. Typhimurium cells were pelleted at 15000 g for 1 min, and 
pellets were lysed with 200 μL lysis buffer (phosphate-buffered saline (PBS) containing 0.5% 
Nonidet P-40, 1X EDTA-free protease inhibitor cocktail (Roche), 0.5 mg/mL lysozyme (in dH2O) 
(Sigma), and 1:1,000 dilution of Benzonase (Millipore)). After re-suspension, pellets were 
sonicated for 10 sec for 3 times, then were incubated on ice for 30 min. Cell lysates were 
centrifuged at 15000 g for 1 min to remove cell debris and supernatants were collected. Protein 
concentration was estimated by BCA assay with BCA Protein Assay Kit (Thermo). 
Salmonella protein immunoprecipitation and immunoblotting 
From Salmonella total cell lysates prepared as described above, protein samples were boiled with 
1X Laemmli buffer 95°C for 5 min. 20 uL of each sample was loaded onto a 4-20% Tris-HCl gel 
(Bio-Rad) for SDS-PAGE. Proteins were transferred onto 0.45 μm nitrocellulose membrane (Bio-
Rad) with Trans-Blot Turbo Transfer System (Bio-Rad) at 25 V for 30 min. Membrane was blocked 
with 5% non-fat milk in PBS with 0.1% Tween-20 (PBS-T) for 30 min, and primary antibody was 
added to solution before incubating membrane at 4°C overnight. Dilution of primary antibodies 
were as follows: for HA-tagged proteins, 1:2,000 anti-HA rabbit antibody H6908 (Sigma); for 
FLAG-tagged proteins, 1:2000 anti-FLAG rabbit antibody F7425 (Sigma); for HilA-K90Bu antigen, 
1:200 anti-HilAK90Bu rabbit custom antibody (Thermo Fisher) or 1:200 anti-HilAK90 rabbit 
custom antibody (Thermo Fisher). Membrane was washed with PBS-T 3 times, and incubated 
with 1:10,000 goat polyclonal anti-rabbit HRP ab97051 (Abcam) in PBS-T with 5% non-fat milk at 
room temperature for 1 hour. Membrane was washed with PBS-T 3 times, and imaged with Clarity 
Western ECL substrate (Bio-Rad) and ChemiDoc XRS+ System (Bio-Rad).    
For Salmonella protein immunoprecipitation, 250 μg of each total cell lysates were incubated with 
20 μL PBS-T-washed EZview™ Red Anti-HA Affinity Gel (Sigma) at 4 °C for 1 hour with end-to-
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end rotation. Samples were washed with 200 μL PBS-T for 3 times, before being boiled with 1X 
Laemmli buffer 95°C for 5 min. 20 uL of each sample was loaded onto a 4-20% Tris-HCl gel (Bio-
Rad) for SDS-PAGE and further immunoblotting. 
 
In-gel fluorescence analysis of LCFA reporter labeling 
For in-gel fluorescence analysis of alk-16 labeled Salmonella proteome, from the alk-16-treated 
or control total cell lysates prepared as described above, 45 μL of each total cell lysates (~50 μg) 
was added with 5 μL of click chemistry reagents as a 10X master mix (az-Rho: 0.1 mM, 10 mM 
stock solution in DMSO; tris(2-carboxyethyl)phosphine hydrochloride (TCEP): 1 mM, 50 mM 
freshly prepared stock solution in dH2O; tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA): 
(0.1 mM, 2 mM stock in 4:1 t-butanol: DMSO); CuSO4 (1 mM, 50 mM freshly prepared stock in 
dH2O). Samples were mixed well and incubated at room temperature for 1 h. After incubation, 
samples were mixed with 200 μL cold methanol, 150 μL cold water, and 75 μL cold chloroform. 
Sample proteins were precipitated at 18000 g for 1 min at 4 °C. After gently removing the aqueous 
layer, protein pellets were washed with 200 μL cold methanol, spinning down at 18000 g for 1 min 
at 4 °C, and liquid was gently decanted. After washing twice, pellets were allowed air-dried before 
boiling with 1X Laemmli buffer.   
For in-gel fluorescence analysis of alk-16 or HDYOA labeled HilA, from the alk-16 or HDYOA-
treated or control total cell lysates prepared as described above, 250 μg of each total cell lysates 
were immunoprecipitated with 20 μL PBS-T-washed EZview™ Red Anti-HA Affinity Gel (Sigma). 
After samples were washed with 200 μL PBS-T for 3 times, 36 μL of PBS was added to each 
sample. 4 μL of click chemistry reagents as a 10X master mix mentioned above were added to 
each sample. Samples were mixed well and incubated at room temperature for 1 h. After 
incubation, samples were washed with 200 μL PBS-T for 3 times.  
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Samples were boiled with 1X Laemmli buffer 95°C for 5 min before being loaded onto a 4-20% 
Tris-HCl gel (Bio-Rad) for SDS-PAGE. In-gel fluorescence scanning was performed using a 
Typhoon 9400 imager (Amersham Biosciences). 
 
Alk-16 labeling Label-Free Quantitative proteomics 
1:50 dilutions of overnight Miller LB cultures of Salmonella Typhimurium strain 14028 WT 
overnight culture were grown in 20 mL SPI-1 inducing LB for 4 h at 37°C with 220rpm shaking, 
each sample growing in 4 mL aliquots. Cultures were incubated with or without 100 uM fresh alk-
16 (in DMSO). Cultures were pooled back to 20 mL per sample in Falcon tubes, and lysed in lysis 
buffer described above. After re-suspension in 1 mL lysis buffer, bacteria were sonicated for 15 
sec with Sonic Dismembrator Model 500 (Fisher Scientific) with 5 sec on and 10 sec off per cycle. 
Cell lysates were centrifuged at 15000 g for 1 min to remove cell debris and supernatants were 
collected. Each total cell lysates (~2 mg) was added with 100 μL of click chemistry reagents as a 
10X master mix (az-Biotin: 0.1 mM, 10 mM stock solution in DMSO; tris(2-carboxyethyl)phosphine 
hydrochloride (TCEP): 1 mM, 50 mM freshly prepared stock solution in dH2O; tris[(1-benzyl-1H-
1,2,3-triazol-4-yl)methyl]amine (TBTA): (0.1 mM, 2 mM stock in 4:1 t-butanol: DMSO); CuSO4 (1 
mM, 50 mM freshly prepared stock in dH2O). Samples were mixed well and incubated at room 
temperature for 1 h. After incubation, samples were mixed with 4 mL cold methanol and incubated 
at -20°C overnight. Protein pellets were centrifuged at 5000 g for 30 min at 4°C, and were washed 
with 1 mL cold methanol 3 times. After last wash, pellets were let air dried before being re-
solubilized in 250 uL 4% SDS PBS with bath sonication. Solutions were diluted with 750 uL PBS, 
and incubated with 60 uL PBS-T-washed High Capacity NeutrAvidin agarose (Pierce) at room 
temperature for 1 h with end-to-end rotation. Agarose were washed with 500 uL 1% SDS PBS 3 
times, 500 uL 2M Urea PBS 3 times, and 500 uL PBS 3 times. Agarose were then reduced with 
100 uL 10 mM DTT (Sigma) in PBS for 30 min at 37°C, and alkylated with 100 uL 50 mM 
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iodoacetamide (Sigma) in PBS for 20 min in dark. On-bead proteins were digested with 400 ng 
Trypsin/Lys-C mix (Promega) at 37°C overnight with shaking. Digested peptides were collected 
and lyophilized before being desalted with custom-made stage-tip containing Empore SPE 
Extraction Disk (3M). Peptides were eluted with 2% acetonitrile, 2% formic acid in dH2O.  
Peptide LC-MS analysis was performed with a Dionex 3000 nano-HPLC coupled to an Orbitrap 
XL mass spectrometer (Thermo Fisher). Peptide samples were pressure-loaded onto a home-
made C18 reverse-phase column (75 µm diameter, 15 cm length). A 180-minute gradient 
increasing from 95% buffer A (HPLC grade water with 0.1% formic acid) and 5% buffer B (HPLC 
grade acetonitrile with 0.1% formic acid) to 75% buffer B in 133 minutes was used at 200 nL/min. 
The Orbitrap XL was operated in top-8-CID-mode with MS spectra measured at a resolution of 
60,000@m/z 400. One full MS scan (300–2000 MW) was followed by three data-dependent scans 
of the nth most intense ions with dynamic exclusion enabled. Peptides fulfilling a Percolator 
calculated 1% false discovery rate (FDR) threshold were reported. 
Label-free quantification of alk-16 labeled proteins was performed with the label-free MaxLFQ 
algorithm in MaxQuant software as described (54). The search results from MaxQuant were 
analyzed by Perseus (http://www.perseusframework.org/). Briefly, the control replicates and alk-
16 labeled sample replicates were grouped correspondingly. The results were cleaned to filter off 
reverse hits and contaminants. Only proteins that were identified in all alk-16 labeled sample 
replicates and with more than two unique peptides were subjected to subsequent statistical 
analysis. LFQ intensities were used for measuring protein abundance and logarithmized. Signals 
that were originally zero were imputed with random numbers from a normal distribution, whose 
mean and standard deviation were chosen to best simulate low abundance values below the 
noise level (Replace missing values by normal distribution – Width = 0.3; Shift = 2.2). Significant 
proteins that were more enriched in alk-16 labeled sample group versus control group were 
determined by a volcano plot-based strategy, which combined t test p-values with ratio information. 
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A hyperbolic significance curve in the volcano plot corresponding to a given FDR (= 0.05) and S0 
value (= 2) was determined by a permutation-based method. The resulting table was exported as 
Appendix 3.1. 
 
Salmonella in vivo photo-crosslinking 
 
For small-scale experiment, 4 mL of Salmonella amber mutants expressing PylRS-ASF mutant 
were grown in the presence of 0.01% arabinose and 100 uM DiZPK. After 4 hours, bacterial cells 
were pelleted at 15000 g for 1 min, and resuspended in 1 mL PBS. After cell suspensions were 
transferred to 6-well plate, samples were photo-crosslinked in XL-1000 UV Crosslinker 
(Spectronics Corporation) for 5 min, with samples about 3 cm from the lamp on ice. Cells were 
lysed, immunoprecipitated, and immunoblotted as described above.  
For large-scale purification and identification, 20 mL of Salmonella amber mutants expressing 
PylRS-ASF mutant were grown in the presence of 0.01% arabinose and 100 uM DiZPK. Cells 
were resuspended in 5 mL PBS and photo-crosslinked as described above. Lysates were 
immunoprecipitated with 50 uL PBS-T washed anti-HA magnetic beads (Pierce). Samples were 
run on SDS-PAGE and stained with SafeStain Coomassie Blue. Crosslinked bands as well as 
control bands were cut out with clean blazers and diced into 1 mm x 1mm cubes. Gels were 
processed per in-gel digestion protocol described previously (218) and sent to The Rockefeller 
Proteomics Resource Center for protein identification.  
 
Salmonella Quantitative Reverse-Transcription PCR  
500 uL of Salmonella cultures were processed with RNeasy Mini Kit (Qiagen) per manufacturer’s 
manual. Concentrations of purified RNA were normalized to 100 ng/uL with RNase-free water. 
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Quantitative Reverse-Transcription PCR (qRT-PCR) were performed with Power SYBR Green 
RNA-to-CT 1-Step Kit (Applied Biosystems) per manufacturer’s manual and primers listed in 
Appendix Table 2.  
 
In vitro invasion assay and intracellular survival assay 
HeLa cells were cultured in 12-well tissue culture plates at 80-90% confluency. Wells were added 
with Salmonella cells at an MOI = 10:1 and centrifuged at 1000 g for 5 min. Cells were incubated 
at 37°C with 5% CO2 for 30 min to allow invasion. The media was then replaced with medium 
containing 100 μg/mL gentamicin and incubated for an additional hour to kill extracellular 
Salmonella. Wells were then washed 3 times with PBS, and cells were lysed with 500 uL 1% 
Triton X-100 PBS. Lysates were serially diluted and drip-dropped on Salmonella Shigella agar 
plates (BD 211597) to determine the number of invaded bacteria. 
 
Quantification and Statistical Analysis 
Comparisons and statistical tests were performed as indicated in each figure legend. Briefly, 
Pairwise comparisons were generated with two-tailed t tests. For comparisons of multiple groups 
over time or with two variables, a two-way analysis of variance (ANOVA) was used with an 
appropriate Bonferroni posttest comparing all groups to each other, all groups to a control, or 
selected groups to each other. Survival data were analyzed using a log-rank (Mantel-Cox) test 
with a Bonferroni correction for the degrees of freedom based on the number of comparisons 
made. To compare two groups with non-normal distribution or low sample size, the medians of 
the two groups were compared using a Mann-Whitney test, unless one data set contained only 
zero values. In these cases, a Mann-Whitney test could not be performed because all values in 
the group were identical; a Wilcoxon test was performed instead. For comparisons of multiple 
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groups with only one variable, a one-way ANOVA or Kruskal-Wallis test was performed for data 
with underlying normal or non-normal distribution, respectively, with Bonferroni, Dunnett’s, or 
Dunn’s posttests where appropriate. Statistical analyses were performed in GraphPad Prism 
software. A P value of less than 0.05 was considered significant, denoted as *P ≤ 0.05, **P ≤ 
0.01, and ***P ≤ 0.001 for all analyses. 
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Summary and Future Outlook 
91 
Recent research has revealed many mechanisms by which gut microbiota influences host 
immunity to defend against invading pathogens, but how microbiota directly antagonizes 
pathogen virulence is less studied. In this thesis, I describe how fatty acids, derived from both gut 
microbiota and diet, contribute to attenuation of virulence of enteric pathogen Salmonella. 
In Chapter 1, I review how dietary and microbiota metabolites affect different aspects of host-
microbe interactions. These metabolites are classified into microbial-associated molecular 
patterns and microbiota-derived secondary metabolites. Small molecules reviewed in this chapter 
not only enhances host innate and adaptive immunity, but also directly inhibit virulence of invading 
pathogens, providing colonization resistance to the host. These findings highlight the importance 
of understanding the intricate interactions between host and microbiota, and should provide 
insights in developing microbiota-targeting therapeutics for host physiology, immunity, and 
pathogen resistance.  
In Chapter 2, I describe a mechanism by which microbiota-derived short-chain fatty acids inhibit 
virulence of Salmonella Typhimurium. We use a chemical reporter strategy to identify molecular 
targets of short-chain fatty acids in Salmonella. I demonstrate that alkynyl-functionalized short-
chain fatty acids can be metabolized and covalently attached to proteins in Salmonella. Proteomic 
analysis reveal that HilA, a key virulence transcription regulator, is short-chain fatty acylated. I 
employ Amber Suppression Technology and CRISPR-Cas9 genome editing to faithfully mimic 
butyrylation on endogenous HilA. Biochemical and functional characterization show that acylation 
of HilA has site-specific effect, and K90 butyrylation affect HilA DNA-binding activity and 
Salmonella invasion in mice. Overall, our results discover a mechanism by which gut microbiota 
provides resistance against Salmonella through short-chain fatty acids.  
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In Chapter 3, I find that dietary long-chain fatty acids potently inhibit Salmonella virulence. 
Chemical proteomics with alkynyl-functionalized long-chain fatty acids reveal proteins that are 
long-chain fatty acylated in Salmonella, including HilA. Modification by long-chain fatty acids on 
HilA is post-translationally N-linked. Moreover, with photo-crosslinking unnatural amino acid, we 
discover that HilA forms homo-oligomers in Salmonella. Our data suggest that dietary long-chain 
fatty acids may interfere pathogenesis of Salmonella through post-translational modification, and 
further structural characterization of HilA may reveal novel target for treatment of Salmonella 
infection.  
According to sequence homology, HilA belongs to OmpR/PhoB Response Regulator (RR) 
subfamily, which represents about one-third of all RRs. Response Regulators (RRs) are members 
within bacterial two-component systems that enable fast response to environmental signals and 
is critical for regulation of bacterial physiology. In most cases, RRs are activated by phosphate 
transfer from a cognate sensory histidine kinase to its aspartate residue in the receiver domain. 
Activated RRs then exert its function through its effector domain. OmpR/PhoB family RRs are 
often activated through phosphorylation-dependent mechanism. However, a lot of atypical 
OmpR/PhoB family RRs are activated through phosphorylation-independent mechanism (219, 
220). For example, HP1043, an atypical OmpR/PhoB family RR in Helicobacter pylori, binds to 
inverted repeat DNA sequence motifs with unknown regulatory activity (220–222). The aspartate 
that should have been phosphorylated in HP1043 is replaced by a lysine residue (221). Indeed, 
Asp67 of HilA, the conserved Asp residue that is supposed to be phosphorylated predicted by 
homology, could not be detected with phosphorylation (185). Our data suggests that Asp67 is 
unlikely to be in the receiver domain, as both Lys57 and Lys90, two residues flanking Asp67, 
resides in DNA-binding domain and directly affect DNA-binding activity of HilA. So far, no cognate 
sensory kinase for HilA has been reported. Our studies have demonstrated that HilA itself may 
be a sensor of environmental fatty acids, including short-chain fatty acids from the gut microbiota 
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and long-chain fatty acids from the diet. HilA may have evolved to use lysine residues instead of 
aspartate to sense environmental metabolites and regulate Salmonella virulence. Our research 
indicates that post-translational fatty acylation may represent one the sensing mechanisms by 
atypical OmpR/PhoB family RRs to environmental signals.  
Even among atypical OmpR/PhoB family RR members, HilA is peculiar. RRs usually have an N-
terminal receiver domain and a C-terminal effector domain (in most cases DNA-binding domain), 
yet HilA adopts a swapped domain architecture, with an N-terminal DNA-binding domain and a 
C-terminal TPR domain with unknown function. OmpR/PhoB family RRs often form homodimers 
and recognize tandem or inverted repeating DNA elements for transcription regulation (223, 224). 
Yet the DNA-binding motif of HilA remains debated. Lostroh and Lee reported that HilA binds to 
a direct repeat sequence motif termed ‘HilA Box’ (181), but De Keersmaecker et al. identified 
other loci that were bound by HilA do not contain ‘HilA Box’ (182). They proposed a new ‘HilA 
Box’ motif (182), yet on closer analysis, that is essentially -35 element in prokaryotic promoters. 
The selectivity of HilA DNA-binding domain remains a mystery. Our HilA ChIP-Seq data may 
provide hints on the DNA motifs, and further in-depth data analysis is required.  
While HilA may act as a sensor for fatty acids in Salmonella, Salmonella as well as other intestinal 
bacteria uses other proteins and mechanisms to sense fatty acids too. In the presence of high 
concentrations of fatty acids, bacterial cytoplasm would accumulate high-energy fatty acid 
intermediates, including fatty acyl-CoA and fatty acyl-phosphate (194, 195, 225). Chemical 
acylation of proteins by these intermediates as well as enzymatic acylation influences bacterial 
metabolism and physiology. For instance, dynamic acetylation level on metabolic enzymes in 
Salmonella regulates the direction of glycolysis versus gluconeogenesis, and the branching 
between citrate cycle and glyoxylate bypass (173). RcsB, a global regulatory RR that controls 
cells division, as well as capsule and flagellum biosynthesis in many bacteria, could be acetylated 
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through both enzymatic acetylation (226) and chemical acetylation (227), which inhibits its DNA 
binding activity. Similarly, PhoP, another highly conserved RR in bacteria that regulate many 
aspects of bacterial physiology including virulence, is dynamically acetylated at K201 that 
regulates its DNA binding ability (228). Fatty acids could be sensed through non-covalent binding 
mechanism as well. Virulence regulator HilD in Salmonella could bind to long-chain fatty acids 
and attenuate its DNA binding activity (204). Vibrio cholerae master virulence regulator ToxT 
could bind to cis-palmitoleate, which would affect ToxT DNA binding and reduce expression of 
toxin-coregulated pilus and cholera toxin in V. cholerae (229, 230). All the examples above 
highlight the diverse mechanisms that intestinal bacteria use to sense and respond to the same 
sets of environmental signals, fatty acids. 
Regulatory functions of acylation are also conserved in eukaryotes. Of note, acetylation has been 
well described as a post-translational modification that dynamically regulate cell physiology. The 
best example may be the ‘histone code’, which started with the discovery of acetylation on histone 
tails (231) and identification of Gcn5 family histone acetyltransferase (232). Dynamic acetylation 
on histone proteins regulates gene transcription, and is involved in inflammatory diseases (233), 
cancer (234), and other disorders (235–237). Interestingly, acetylation of histones appears to be 
responsive to acetyl-CoA level and regulates growth of budding yeast (238). Another example is 
the acetylation of p53, which regulates its DNA binding activity and transcription of p-53-
responsive genes (239). With the advance of detection methods, many novel types of acylation 
have been reported, including propionylation (240), butyrylation (240), 2-hydroxyisobutyrylation 
(241), succinylation (242), malonylation (242), glutarylation (243), crotonylation (244), and -
hydroxybutyrylation (245), which collectively may regulate signal-dependent gene activation and 
metabolic stress (246, 247). Some of these modifications are conserved in bacteria (248, 249), 
and future studies on the functional consequences of these acylations in bacteria will help 
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elucidate mechanisms metabolic sensing by microbiota and guide metabolic approaches to 




Appendix Table 1. Bacterial strains used in this thesis. Strains are from Hang lab or generated 
in the thesis unless otherwise noted.  















































































































































































































































































































































Appendix Table 2. Primers used for qRT-PCR and ChIP-qPCR in this thesis. 
No. Primer Name Sequence (5’ to 3’) 
73 invF qPCR F TCCTGAGTTTCGCGCTATTT 
74 invF qPCR R GTAACAGCGCCAGTACCTTAT 
75 prgH qPCR F ACAGCAGGCGTTACCTTATTC 
76 prgH qPCR R AATTGACGGGCTCTGAGTATTT 
157 spaO qPCR F CCGACCAATGCTGAACTTAAC 
158 spaO qPCR R TTCATGGATCTCAACGCCTAAG 
159 orgB qPCR F ATCAGACAATGGCCTGGAAG 
160 orgB qPCR R AAATCCCTTAGCCACTCATCC 
199 PprgH qPCR F AGAACGACAGACATCGCTAAC 
200 PprgH qPCR R CCGTTCAGTGAGCTGTTAAGTA 
201 PinvF qPCR F GGGCGGCATCAGTTTCATAA 
202 PinvF qPCR R GCATAGTTGTCAGCACCAGTTA 
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Appendix 2.1. Table of identified protein targets of Alk-3 in Stm through LFQ proteomic analysis. 
Protein IDs Category Description 
hilA SPI-1 Invasion protein regulator 
sipD SPI-1 Translocation machinery component 
sopB SPI-1 Secreted effector protein 
sipA SPI-1 Secreted effector protein 
sipC SPI-1 Cell invasion protein SipC 
sicA SPI-1 Secretion chaperone 
fabD Metabolism Malonyl CoA-acyl carrier protein transacylase 
gltA Metabolism Citrate synthase 
citD Metabolism Citrate lyase acyl carrier protein 
eno Metabolism Enolase 
panD Metabolism Aspartate 1-decarboxylase 
gcvH Metabolism Glycine cleavage system H protein 
rpiA Metabolism Ribose-5-phosphate isomerase A 
pgk Metabolism Phosphoglycerate kinase 
sucC Metabolism Succinate--CoA ligase [ADP-forming] subunit beta 
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acnB Metabolism Aconitate hydratase B 
asnB Metabolism Asparagine synthetase B 
aspA Metabolism Aspartate ammonia-lyase 
yqhD Metabolism Putative alcohol dehydrogenase 
ribE Metabolism Riboflavin synthase subunit alpha 
maeB Metabolism Malic enzyme 
pykF Metabolism Pyruvate kinase 
dctA Metabolism C4-dicarboxylate transport protein 
tktA Metabolism Transketolase 
pykA Metabolism Pyruvate kinase 
dkgA Metabolism 2,5-diketo-D-gluconate reductase A 
pepD Metabolism Aminoacyl-histidine dipeptidase 
nuoB Metabolism NADH-quinone oxidoreductase subunit B 
glyA Metabolism Serine hydroxymethyltransferase 
trxA Metabolism Thioredoxin 
icdA Metabolism Isocitrate dehydrogenase [NADP] 
guaC Metabolism GMP reductase 
talB Metabolism Transaldolase 
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phoN Metabolism Acid phosphatase 
gapA Metabolism Glyceraldehyde-3-phosphate dehydrogenase 
cysK Metabolism Cysteine synthase 
prsA Metabolism Ribose-phosphate pyrophosphokinase 
tdcE Metabolism Pyruvate formate-lyase 4/2-ketobutyrate formate-lyase 
adhE Metabolism Aldehyde-alcohol dehydrogenase 
tyrS Metabolism Tyrosine--tRNA ligase 
dnaK Others Chaperone protein DnaK 
ydhD Others Glutaredoxin 
grxC Others Glutaredoxin 
yghA Others Oxidoreductase 
nifU Others Iron-sulfur cluster assembly scaffold protein IscU 
groEL Others 60 kDa chaperonin 
yfiD Others Autonomous glycyl radical cofactor 
hns Others DNA-binding protein H-NS 
katE Others Catalase 
tpx Others Thiol peroxidase 
erpA Others Iron-sulfur cluster insertion protein ErpA 
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greA Others Transcription elongation factor GreA 
STM14_5121 Others Putative inner membrane protein 
yfiE Others Putative LysR family transcriptional regulator 
pmbA Others Peptidase PmbA 
yhgI Others Fe/S biogenesis protein NfuA 
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Appendix 3.1. List of identified protein targets of Alk-16 in Stm through LFQ proteomic analysis. 





5.295718 6.580152 sipA Secreted effector protein 
4.596443 6.067259 sopB Inositol phosphate phosphatase SopB 
4.13649 5.121576 sipC Cell invasion protein SipC 
6.095165 4.877037 sipD Cell invasion protein SipD 
2.53398 3.625011 sicA Chaperone protein SicA 
1.748172 3.163045 sopE2 Guanine nucleotide exchange factor sopE2 
3.285982 2.883593 sptP Secreted effector protein SptP 
3.469847 2.314409 hilA Transcriptional regulator HilA 
1.132367 1.464825 sopA E3 ubiquitin-protein ligase SopA 
1.763296 7.616678 lpp1 Major outer membrane lipoprotein 1 
2.750863 6.559837 acpP Acyl carrier protein 
3.096859 6.383107 pgk Phosphoglycerate kinase 
4.407329 5.763006 cadA Lysine decarboxylase 
5.138377 5.438326 ackA Acetate kinase 
3.090379 5.404028 pepD Aminoacyl-histidine dipeptidase 
3.898353 5.334023 osmE DNA-binding transcriptional activator OsmE 
4.931134 5.27616 yqhD Putative alcohol dehydrogenase 
4.530829 5.196304 arcA Arginine deiminase 
4.57988 5.141149 hns DNA-binding protein H-NS 
4.250792 4.936145 acrA Acridine efflux pump 
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4.366618 4.865341 tpiA Triosephosphate isomerase 
5.431065 4.8517 sspA Stringent starvation protein A 
5.223858 4.850132 alaS Alanine--tRNA ligase 
4.132562 4.770939 manZ Mannose-specific PTS system protein IID 
5.108081 4.728649 yaeH UPF0325 protein YaeH 
3.584452 4.693852 icdA Isocitrate dehydrogenase [NADP] 













ClpB protein (Heat shock protein f84.1) 
3.93975 4.447678 ybis Putative L,D-transpeptidase YbiS 
2.529688 4.382948 rpiA Ribose-5-phosphate isomerase A 
5.23199 4.363451 sucC Succinyl-CoA ligase [ADP-forming] subunit beta 
1.892263 4.302311 dnaK Chaperone protein DnaK 
4.200961 4.257231 galU UTP--glucose-1-phosphate uridylyltransferase subunit 
GalU  
5.819958 4.253464 kdsA 2-dehydro-3-deoxyphosphooctonate aldolase 
4.314986 4.210491 fabI Enoyl-[acyl-carrier-protein] reductase [NADH] FabI 
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5.031606 4.200387 ptsI Phosphoenolpyruvate-protein phosphotransferase 
3.185759 4.171696 eno Enolase 





4.844141 4.1238 nuoL NADH dehydrogenase subunit L 
3.529328 4.120824 deoB Phosphopentomutase 
1.605582 4.050425 fbaB Fructose-bisphosphate aldolase 
3.909793 3.985844 acnB Aconitate hydratase 2 
4.419057 3.923382 adk Adenylate kinase 
4.563996 3.911688 minD Site-determining protein 
2.279087 3.896372 frdA Fumarate reductase, flavoprotein subunit 
1.51704 3.856174 slyB Outer membrane lipoprotein SlyB 
2.793875 3.838635 sucD Succinyl-CoA ligase [ADP-forming] subunit alpha 
3.937432 3.814405 glpK Glycerol kinase 
5.352378 3.801908 sdhB Succinate dehydrogenase iron-sulfur subunit 
4.735745 3.737444 nuoF NADH-quinone oxidoreductase subunit F 
2.224313 3.735641 frdB Fumarate reductase iron-sulfur subunit 
3.373764 3.731722 ucpA Oxidoreductase UcpA 






1.878152 3.666236 clpX ATP-dependent Clp protease ATP-binding subunit 
ClpX  
4.74674 3.658666 crp cAMP-activated global transcriptional regulator CRP 
5.391827 3.653837 purA Adenylosuccinate synthetase 
3.12594 3.630978 glpT sn-glycerol-3-phosphate transporter 





1.540743 3.597588 cyoB Cytochrome o ubiquinol oxidase subunit I 
2.761849 3.541516 uspF Universal stress protein F 
3.553989 3.507147 hldD ADP-L-glycero-D-manno-heptose-6-epimerase 
4.003492 3.49936 engD Ribosome-binding ATPase YchF 
5.152183 3.481234 gnd 6-phosphogluconate dehydrogenase, decarboxylating 
1.469702 3.451141 deoD Purine nucleoside phosphorylase DeoD-type 
5.51632 3.429234 pheT Phenylalanine--tRNA ligase beta subunit 
3.090018 3.420237 tufA Elongation factor Tu 
2.059706 3.416838 fabB 3-oxoacyl-(Acyl carrier protein) synthase I 
5.177576 3.342725 hldE Bifunctional protein HldE 
1.920311 3.330688 grxA Glutaredoxin-1 
4.319432 3.325662 glmS Glutamine--fructose-6-phosphate aminotransferase 
[isomerizing]  
5.492707 3.313935 eutB Ethanolamine ammonia-lyase heavy chain 





Fructose 1,6-bisphosphate aldolase 
3.768561 3.233645 argS Arginine--tRNA ligase 
1.699932 3.221724 grxC Glutaredoxin 3 
4.27221 3.209486 talB Transaldolase B 
4.73276 3.207051 malK Maltose/maltodextrin import ATP-binding protein MalK 
4.079357 3.204319 thrS Threonine--tRNA ligase 
2.039398 3.199423 ybjP Putative lipoprotein 
3.932196 3.196885 yliJ Glutathione s-transferase family protein 
3.673113 3.174411 dapA 4-hydroxy-tetrahydrodipicolinate synthase 
1.864859 3.173382 atpF ATP synthase subunit b 
1.535292 3.172801 yghA Oxidoreductase 
3.696875 3.170086 fbp Fructose-1,6-bisphosphatase class 1 
4.018392 3.146297 nifU Scaffold protein 
3.670025 3.113139 leuS Leucine--tRNA ligase 
3.72587 3.105 gst Glutathionine S-transferase 
2.026667 3.103836 pykF Pyruvate kinase 
3.001963 3.051551 torC Trimethylamine N-oxide reductase cytochrome c-like 
subunit  





5.158218 2.994371 yebC Probable transcriptional regulatory protein YebC 
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1.541114 2.987154 rfbH Lipopolysaccharide biosynthesis protein RfbH 
5.005963 2.973447 rpsA 30S ribosomal protein S1 
4.120244 2.964425 uspA Universal stress protein A 
5.918274 2.956854 pfkB Phosphofructokinase 
1.509733 2.92706 ygaM YgaM protein 
3.131615 2.923406 fljB Phase 2 flagellin 
0.805356 2.919812 yajQ UPF0234 protein YajQ 
1.736869 2.900527 yfcZ Uncharacterized protein 
1.524307 2.89203 arcB Ornithine carbamoyltransferase, catabolic 
2.419709 2.885463 gudD D-glucarate dehydratase 
1.974192 2.870841 ndk Nucleoside diphosphate kinase 
2.177368 2.868642 secB Protein-export protein SecB 
3.435057 2.864764 rof ROF protein 
1.783416 2.84557 tkt Transketolase 




Succinate dehydrogenase flavoprotein subunit 
1.962253 2.818172 garR Tartronate semialdehyde reductase 
2.222904 2.817016 prs Ribose-phosphate pyrophosphokinase 
3.144408 2.814523 tyrS Tyrosine--tRNA ligase 
2.982671 2.80989 pykA Pyruvate kinase II 










2.606342 2.742773 citT Citrate/succinate transport antiport protein 
1.661152 2.730909 yieF Putative oxidoreductase 
3.582162 2.720367 aceE Pyruvate dehydrogenase E1 component 
4.148295 2.717626 bcp Thioredoxin-dependent thiol peroxidase 








Putative secreted protein 
3.262089 2.639904 valS Valine--tRNA ligase 
3.052889 2.612987 hemL Glutamate-1-semialdehyde 2,1-aminomutase 
3.763151 2.606649 tktA Transketolase 




ATPase domain protein 
1.797721 2.560793 traT Conjugative transfer surface exclusion protein 
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2.844748 2.55012 glnA Glutamine synthetase 




L-serine deaminase 1 
2.249804 2.521631 serS Serine--tRNA ligase 
3.39602 2.517659 gcvP Glycine dehydrogenase (decarboxylating) 
2.901281 2.436315 aspS Aspartate--tRNA ligase 
1.611601 2.427409 ftn Ferritin 
2.488933 2.419221 kbl 2-amino-3-ketobutyrate coenzyme A ligase 
2.331812 2.381566 ygiB UPF0441 protein YgiB 
2.895535 2.37863 recA Protein RecA 
1.327359 2.336936 pnp Polyribonucleotide nucleotidyltransferase 
2.887168 2.330995 prlC Oligopeptidase A 
2.342801 2.317223 pflB Formate acetyltransferase 1 
1.866763 2.307178 cheA Chemotaxis protein CheA 
1.859378 2.286694 malE Maltose-binding periplasmic protein 
1.523602 2.285541 tdcG L-serine deaminase 
1.692734 2.284634 glnB Nitrogen regulatory protein P-II 1 
1.111207 2.279823 atpD ATP synthase subunit beta 
2.402536 2.272444 tsf Elongation factor Ts 
0.785455 2.259772 ompA Outer membrane protein A 
2.023052 2.253075 aspC Aspartate aminotransferase 










NADP-dependent malate dehydrogenase 
(Decarboxylating)  
3.206656 2.226079 rpoD RNA polymerase sigma factor RpoD 
3.614921 2.193863 glyA Serine hydroxymethyltransferase 
3.353257 2.188644 metK S-adenosylmethionine synthase 
3.954331 2.163292 fusA Elongation factor G 
2.321782 2.16064 aldB Aldehyde dehydrogenase B 
1.839531 2.155278 pepP Proline aminopeptidase II 
3.26356 2.147752 pyrG CTP synthase 
1.866638 2.140305 iadA Isoaspartyl dipeptidase 
1.142182 2.135898 lysS Lysine--tRNA ligase 
1.95664 2.134546 rfbG CDP-glucose 4,6-dehydratase 
3.693331 2.134274 hybC Hydrogenase-2, large subunit 
2.000398 2.132262 tig Trigger factor 




Nucleoside permease NupC 
1.040718 2.103135 nlpB Outer membrane protein assembly factor BamC 
1.725687 2.099536 guaA GMP synthase [glutamine-hydrolyzing] 
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1.642941 2.099028 acnA Aconitate hydratase 
2.815118 2.085762 tsaB tRNA threonylcarbamoyladenosine biosynthesis 




Methyl-accepting chemotaxis protein II 
0.962423 2.078973 dcuB Anaerobic C4-dicarboxylate transporter 
3.317019 2.071259 pepN Aminopeptidase N 
2.979041 2.060308 pckA Phosphoenolpyruvate carboxykinase [ATP] 
2.78949 2.05892 sodB Superoxide dismutase 
2.522927 2.04125 nuoG NADH-quinone oxidoreductase subunit G 




Putative glycosyl hydrolase 
1.149125 1.991829 pntA NAD(P) transhydrogenase subunit alpha 
1.421445 1.984356 speF Ornithine decarboxylase 
1.487247 1.972696 upp Uracil phosphoribosyltransferase 
1.044659 1.971578 rplK 50S ribosomal protein L11 
0.883421 1.966462 nuoB NADH-quinone oxidoreductase subunit B 




L-serine dehydratase 2 (L-serine deaminase 2) 
1.293747 1.886269 malF Maltose transport system permease protein MalF 
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1.035021 1.885867 rplE 50S ribosomal protein L5 
2.973231 1.876769 typA GTP-binding protein 
1.119039 1.842197 nrdA Ribonucleoside-diphosphate reductase 1 subunit 
alpha  
1.790733 1.827587 aceF Dihydrolipoyllysine-residue acetyltransferase 
1.754495 1.82602 gyrB DNA gyrase subunit B 
2.68662 1.825929 udp Uridine phosphorylase 
0.778031 1.821534 rplL 50S ribosomal protein L7/L12 
2.298098 1.81606 ppc Phosphoenolpyruvate carboxylase 
0.797527 1.800735 tdcE Pyruvate formate-lyase 4/2-ketobutyrate formate-lyase 
0.935107 1.775652 cydA Cytochrome d terminal oxidase polypeptide subunit I 
1.984189 1.760096 asd Aspartate-semialdehyde dehydrogenase 
1.816843 1.747447 fumA Fumarate hydratase class I, anaerobic 
1.756417 1.738461 fdoG Hypothetical 1 formate dehydrogenase-O, major 
subunit  
4.030025 1.718745 mdh Malate dehydrogenase 
3.111759 1.718309 metG Methionine--tRNA ligase 
1.039016 1.704385 rpoA DNA-directed RNA polymerase subunit alpha 
1.588926 1.650065 maeA NAD-dependent malic enzyme 
1.457687 1.630216 eutM Ethanolamine utilization protein EutM 
2.138438 1.627711 fumC Fumarate hydratase class II 
1.988542 1.624924 pepQ Xaa-Pro dipeptidase 
1.368701 1.589605 glpQ Glycerophosphodiester phosphodiesterase 
2.110415 1.589405 glyS Glycine--tRNA ligase beta subunit 
1.89163 1.559617 zwf Glucose-6-phosphate 1-dehydrogenase 
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0.863203 1.543272 rpmB 50S ribosomal protein L28 




Uptake hydrogenase-1 large subunit 
1.894378 1.495006 rihA Pyrimidine-specific ribonucleoside hydrolase RihA 
2.392272 1.484539 ldhA D-lactate dehydrogenase 
1.004855 1.458355 dapD 2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-
succinyltransferase  




Putative methyl-accepting chemotaxis protein 
0.957426 1.428329 rplJ 50S ribosomal protein L10 
3.127597 1.427683 mglB D-galactose-binding periplasmic protein 
0.730977 1.403804 dctA Aerobic C4-dicarboxylate transport protein 
1.028964 1.401089 cysK Cysteine synthase A 




Arabinose 5-phosphate isomerase 
1.718342 1.315477 yeaG Putative serine protein kinase 
1.675064 1.26836 yifE UPF0438 protein YifE 
1.916112 1.257701 arnC Undecaprenyl-phosphate 4-deoxy-4-formamido-L-
arabinose transferase  
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1.425214 1.153601 ppa Inorganic pyrophosphatase 
3.203631 1.15095 talA Transaldolase A 
2.113997 1.121765 asnB Asparagine synthetase 
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